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Abstract 
Epstein-Barr virus is a γ-herpesvirus endemic (>90%) in the human population and 
implicated in a variety of lymphomas and solid tumours including Hodgkin’s lymphoma, 
Burkitt’s lymphoma and post-transplant lymphoproliferative disorder. Despite the 
prevalence of EBV, little is known about the mechanisms of early infection, including the 
role of the various membrane glycoproteins to entry, fusion and escape. Additionally, 
although the long term immune response is well characterised, the contribution of CD4+ 
and CD8+ T cell recognition to surveillance of primary cellular infection is not known. In 
order to further understand the processes of virus entry and processing we have used a 
panel of glycoprotein knockout viruses and viral epitope-specific CD4+ CD8+ T cell 
clones to study EBV infection of primary B cells. We have shown that following binding 
uptake is rapid yet selective, with suggested roles for gp42 and gp85 in attachment and 
initiation of fusion. Endocytosis results in rapid up-regulation of primary resting B cell 
endosomal activity, although no further surface-bound EBV is internalised. Endosomal 
trafficking of endocytosed virus is rapid, reaching the late endosomal compartment 
within the first hour, and subsequent HLA class II loading and presentation within 8 
hours of binding. Further, both membrane and capsid proteins were seen in the late 
endosome by confocal, indicating relatively low fusion efficiency. The endocytic/HLA 
class II pathway may therefore offer a promising target for CD4+ T cell immunotherapy 
offering a first line of defence during de novo infection. 
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1 Introduction 
1.1 EBV 
Epstein-Barr virus is a γ-herpesvirus endemic (>90%) in the human population1. 
Primary infection with EBV normally occurs in childhood and is typically asymptomatic. 
However, if delayed until adolescence, primary exposure may present as the acute 
disease infectious mononucleosis (IM)2. First discovered in cultured cells derived from 
Burkitt’s lymphoma a childhood tumour common to the malarial belt of sub-Saharan 
Africa, EBV has subsequently been associated with the development of a variety of 
lymphomas and solid tumours including Hodgkin’s lymphoma (HL) and nasopharyngeal 
carcinoma3. Despite the endemic spread of EBV, and the demonstrated transformative 
capability of EBV on B cells in vitro, incidence of EBV-related malignancy in the general 
population remains low. The importance of continued immune surveillance in 
prevention of progression to malignancy is shown by the increased incidence of EBV-
related malignancies, such as post-transplant lymphoproliferative disorder (PTLD) or 
HL, following immune suppression3.  Structurally, EBV consists of a double stranded 
172kb DNA genome encapsulated by a nucelocapsid. The virus is enveloped with a 
number of glycoprotein spikes with important roles in viral entry and immune 
recognition. In common with other members of the herpesvirus family, following 
infection the virus persists in a latent state with sporadic reactivation into the lytic 
replication cycle resulting in shedding of the virus. Two EBV subtypes EBV-1 & EBV-2 
exist in the wild, differentiated by EBNA2 gene sequence, with EBV-2 less effective at 
transforming B cells in vitro4. 
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1.2 Life cycle of EBV 
While little is known of early lytic to latent infection in vivo, research has established a 
common sequence of gene expression patterns, or latency programmes, in infected B 
cells following infection in vitro (Table 1). Latency III expression is associated with 
expression of up to 9 EBV proteins including nuclear antigens EBNA1, 2, 3A, 3B, 3C and 
LP, and the latent membrane proteins LMP1, 2A and 2B5.  Additionally, two EBV-
encoded no translated RNA are seen during latency EBERs (EBV-encoded RNAs) and 
BARTs (BamH1-A rightward transcripts). Sequential down-regulation of these latency 
genes is central role in EBV evasion of the host immune response. At latency O 
expression of EBNAs and LMPs (except LMP2A) are fully suppressed. 
 
 EBERs EBNA1 LMP1 LMP2A EBNA2 
ENBA3s 
EBNA-LP 
 
O +  - + - - Memory B cells 
I + + - - - - BL, PEL 
II + + + + - - HL 
III + + + + + + PTLD 
IV   -  +  IM, PTLD 
Table 1. EBV gene expression in latency programmes 0-IV. Adapted from Küppers, R. B cells 
under influence 5 
1.2.1 Primary Infection to Latency 
In primary infection EBV enters the host via the oral route (Figure 1). Infection of local 
epithelial cells in the oropharynx results in lytic replication and a high titre shedding of 
virus in the host’s saliva which may persist up to 6 months post-infection6. Infection of 
local tissue B lymphocytes results in a growth transformed latency III population, 
expanding rapidly and migrating to the tonsils and other lymphoid tissues. Following 
infection of the B cell the viral DNA circularises via recombination of N-terminal repeats. 
This gives rise to circular episomes in the nuclei of infected cells, with a variable number 
of terminal repeats, useful in studying the clonality of lymphomas7. The majority of EBV 
positive B cells produced during expansion are eliminated by the emerging cytotoxic T 
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cell response to lytic and latent antigens. However, a proportion of these cells will 
successfully evade immune targeting by the down-regulation of gene expression and 
adoption of a latency 0 expression programme. These infected cells, characterised by 
expression of EBERs and perhaps LMP2A, persist in the host as part of the memory B-
cell reservoir.  
 
 
Latency 0 Latency I/II Latency III Lytic Replication
Memory B cell
reservoir
Germinal
centre
Germinal
centre
Naïve B cell
Naïve B cell
Memory B cell
Memory B cell
Primary T cell
response
Memory T cell
response
Plasma cell
 
Figure 1. Life cycle of EBV. Adapted from Epstein Barr: 40 years on Lawrence S. Young and Alan 
B. Rickinson Nat. Rev. Cancer8 
 
While EBV infects both naïve and memory B cells in vitro it is presently unknown 
whether in vivo EBV directly infects naïve B cells and viral transformation drives the 
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cells into a memory phenotype by mimicking antigen-specific somatic hyper-mutation in 
the germinal centre, or whether pre-existing populations of memory B cells are infected 
directly by EBV. Infected naïve B cells are occasionally observed in the germinal centre 
and do undergo clonal expansion in the absence normal selection. However, infection 
may occur in the germinal centre or alternatively the cells may be infected elsewhere 
and migrate there. However, during acute IM infected B cells are seen to preferentially 
migrate to the extra-follicular space in the tonsils, where expansion in the absence of 
somatic hyper-mutation results in Ig null mature B cells in circulation.  
1.2.2 Latency to Lytic reactivation 
Post infection carrier status is attained, with periodic low level shedding in the saliva of 
the infected host. The lifecycle of Epstein-Barr virus follows the pattern of latency in the 
B cell compartment, with cyclic lytic infection of epithelial cells and shedding from the 
oropharynx via the oral route. In rare cases EBV is also able to infect T cells, NK cells and 
smooth muscle cells and possibly monocytes9, though the mechanisms involved are 
unclear and the role of these cells in the normal EBV life cycle is not known. The 
commitment of a large proportion of the host immune response to EBV lytic antigens 
suggests frequent reactivation and expression of lytic cycle proteins must occur in vivo. 
1.2.3 Cellular and host responses to EBV infection 
Acute infectious mononucleosis is associated with strong cellular immune responses, 
with expansion of oligoclonal EBV specific cytotoxic CD8+ T cells against both lytic and 
latent EBV antigens10. During this period responses to individual lytic epitopes can 
account for up to 40% of the CD8+ T cell population, with latent epitopes accounting for 
just 0.1-5%11. Studies of memory CD8+ responses have focused primarily on healthy 
individuals with no history of IM. These patients typically have lower virus titres in the 
throat and lower numbers of infected B cells in circulation. Appropriately, the majority 
of CD8+ memory cells show a resting phenotype and lack CD38/69 activation markers. 
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However, a proportion of EBV-specific CD8+ memory T cells do express perforin and are 
capable of targeted killing of peptide loaded cells ex vivo12. This EBV specific response is 
maintained in the host, with individual lytic and latent epitopes accounting for 0.2-2% 
and 0.05-1% of the CD8+ T cell population respectively13. In total EBV antigens account 
for approximately 5% of the CD8+ T cell pool, persisting and rising to up to 14% of CD8+ 
T cells by the age of 60 years14. Screening of IM patients has identified CD8+ responses 
to a wide range of lytic antigens including immediate early BZLF1 and BRLF1 and early 
proteins induced by these two including BMLF1, BMRF1, BALF1, BALF515. Responses to 
other early or late antigens are seen in only a small number of patients and at low 
levels10,16. Latent antigens are also targeted for CD8+ response, predominantly from the 
EBNA3 family of proteins, but also LMP2 and EBNA1&2 to a lesser extent17.  
 
The role of the CD4+ response in EBV is less understood. Limited expansion of the CD4+ 
T cell pool is observed during IM in primary infection18 although EBV-specific T cell 
responses are detectable at low levels, comparable to that seen in other viral 
infections19. Responses are to a broad range of lytic and latent antigens including 
immediate early protein BZLF1 and less frequently EBNA120. In contrast to CD8+, 
considerable responses are also seen to late antigens21. Following the acute phase of IM 
CD4+ responses fall rapidly within the following weeks and have been difficult to study 
in detail. However, it has been shown that the majority of EBV-specific CD4+ T cells 
produce IFN-y and TNF-a, with a small proportion producing IL-2, and have a CD45RO+, 
CD27+, CD28+ phenotype18.  Elispot assays show CD4+ memory T cell IFN-y responses 
to both latent EBNA and LMP derived antigens, with up to 60% of Caucasian donors 
recognising epitopes in EBNA1 and EBNA222. However the majority of CD4+ responses 
are directed against lytic cycle antigens including BZLF1, BMLF1 and BHRF1, and to 
envelope glycoproteins gp350 and gp110 which are rarely targeted via the CD8+ 
response23,24. While CD4+ responses have been shown to be required to maintain an 
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effective CD8+ response, it is suggested that additionally some elements of the CD4+ 
response have direct cytotoxic action against latent antigen-positive cells25. While the 
importance of these CD4+ responses in vivo is unclear, the success of immunotherapy in 
lymphoproliferative disease is closely linked to the proportion of lytic antigen specific 
CD4+ T cells infused26. 
1.3 EBV mechanisms of infection 
1.3.1 Attachment 
During infection of B cells, the initial attachment occurs via high affinity interaction 
between gp350/220 and CR2 (CD21) (Figure 2, Table 2). Binding triggers capping of 
CR2 on the B cell surface and subsequent endocytosis of the viral particle into a low pH 
early endosomal compartment27. Antibodies to gp350 and soluble CR2 both inhibit 
infection of B cells via this CR2 dependent mechanism28. Recombinant viruses lacking 
gp350 may still transform B cells but do so with much reduced efficiency, suggesting 
that while not necessarily the only route for B cell entry, it is by far the dominant one29. 
 
Infection of epithelial cells is more complex, with multiple apparently redundant routes 
of attachment. Some epithelial cells do express CR2/CD21at low levels in culture and so 
can be bound by gp35030. However, it is unclear what contribution this makes in vivo as 
in contrast to B cells antibodies to gp350 enhance infection of epithelial cells with the 
binding of anti-gp350 immunoglobulin-A coated virus to the polymeric IgA receptor, 
having a possible role in basolateral infection or trans-migration in epithelia31. Epithelial 
cell infection with cell-free virus shows very poor efficiency32 in vitro however the 
recently discovered mechanism of ‘transfer infection’ from adjacent B cells results in 
much improved uptake33. This has particularly important implications for virus 
shedding during reactivation. IgA antibody release at mucus membranes is dependent 
on close association of plasma B cells and the basolateral epithelium with release of IgA 
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occurring through the epithelial cell via endocytosis34. The close association of 
potentially infected B cells, the much increased infection efficiency via transfer, and the 
putative role of gp350 IgA in epithelial attachment strongly suggests that this 
mechanism may be the predominant route for epithelial cell infection in vivo. Absence of 
CR2 the gHgL (gp85/gp25) complex has additionally been shown to facilitate entry to 
epithelial cells35 via an as yet unknown receptor, and antibody to this complex inhibits 
uptake36. Additionally, a protein encoded by the BMRF2 open reading frame has been 
shown to interact with β1, α5, α3 and αv integrins and may bind epithelial cells32,37, 
although only small quantities of BMRF2 are found in the virus particle38. 
 
 
CR2/CD21
HLA class II
CR2/CD21
HLA class II
B Cell
  
CR2/CD21
HLA class II
HLA class II
Endosome
 
CR2/CD21
HLA class II
CR2/CD21
HLA class II
HLA class II
EBV capsid
EBV genome
 
Figure 2. Schematic of EBV cellular entry and fusion processes in B cells. Binding of gp350 to 
CD21/CR2 of the surface, triggers internalisation to the endocytic pathway. Interaction of gp42 
with HLA class II triggers fusion and release of the viral genome to the cytosol. 
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1.3.2 Fusion & penetration 
Fusion and internalisation of EBV is dependent on the presence of three glycoproteins 
common to all herpesvirus family members: gH, gL and gB (gp85, gp25, gp110)39. 
However, the role and importance of these glycoproteins differs between target cells. 
 
Fusion of EBV with B cells is endocytosis dependent, triggered by the interaction 
between gp350/220 and CR2 on the cell surface40. Fusion occurs in a low pH 
compartment and requires gHgL, gB (gp85) in addition to gp42, a type-II membrane 
protein which associates noncovalently with the gHgL complex. Interaction between this 
gHgLgp42 complex and HLA class II in the endosomal pathway is thought to trigger 
fusion of the viral envelope and penetration of the capsid into the cytosol41. Binding of 
the gp42 to HLA class II is allele specific, with the virus unable to bind to rare HLA-DQs, 
however due the existence of multiple HLA types within an individual it is unlikely to 
have substantial importance in vivo42. Interactions occur with both immature and 
peptide loaded MHC indicating that binding occurs not at the peptide groove itself.  
 
Fusion of EBV with epithelial cells is endocytosis independent and occurs at neutral pH. 
There is no constitutive expression of HLA class II on epithelial cells, and the presence of 
gp42 in the infecting virion is unnecessary and in fact inhibitory for infection43. Wild 
type EBV has lower expression of gp42 than gHgL suggesting that gHgL can operate 
independently to enable epithelial entry by another as yet unknown target. Epithelial 
fusion is also dependent on higher levels of gB than that seen in B cells44, although the 
mechanics of gB in epithelial fusion remain unclear. 
 
As the gHgL and gHgLgp42 complexes differentially aid entry into epithelial and B cells 
respectively, the relative quantity of each complex on the virion surface has been 
suggested as a determinant of viral tropism. Viruses produced in epithelial cells are 
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gHgLgp42 rich, while in B cells the interaction of gp42 with immature HLA class II and 
subsequent degradation results in virions that are gHgLgp42 low, and gHgL high. As a 
result, virus produced in B cells is more able to infect epithelial cells, and likewise, virus 
produced in epithelial cells is more able to infect B cells45.  Binding of EBV to B cell 
surface has subsequently been shown to significantly enhance secondary infection of 
epithelial cells, without internalisation or active infection of the B cell occurring33. 
 
Gene Protein Pass/Type Role in EBV entry  
BLLF1 gp350 Single/1 Attachment B-cell receptor CR2/CD21 
BXLF2 gp85/gH Single/1 Fusion; Attachment epithelial cell co-receptor 
BKRF2 gp25/gL Single/2 gH chaperone 
BZLF2 gp42 Single/2 Fusion interacts with B-cell MHC-II 
BALF4 gp110/gB Single/1 Fusion 
BLRF1 gN Single/1 gM co-dependent, possible post-fusion 
BBRF3 gM Multispan  
BMRF2  Multispan Attachment via integrins polarised epithelial infection 
Table 2. Envelope glycoproteins of EBV involved in B and epithelial cell infection. Lindsey M. 
Hutt-Fletcher. Epstein-Barr Virus Entry (Minireview) JV 200746 
 
1.4 Host processing and presentation of antigens 
Effective adaptive immune responses are dependent on the presentation of peptides 
derived from foreign antigens to the host T cells. Two distinct cellular pathways exist, 
broadly processing endogenous expressed or exogenously acquired antigen, culminating 
in the presentation of antigen on the cell surface via HLA class I and II respectively.  
 
Peptides presented in the endogenous class I pathway are generated from the 
degradation of cytosolic proteins by the proteasome – including both host cell proteins 
and those of infecting agents. Proteosomal degradation is constitutive in all cells, but 
may be up-regulated in infected cells. Degraded proteins are trans-located into the 
endoplasmic reticulum via the transporter associated with antigen processing (TAP). 
Assembly of HLA class I molecules occurs in the endoplasmic reticulum with a complex 
including TAP, calnexin, Erp57, tapasin and calreticulin stabilising the structure until the 
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binding of peptide occurs. Once loaded the assembly complex dissociates and the HLA-I-
peptide complex is transported through the secretory pathway to the cell surface 
undergoing various post-translational modifications in the Golgi apparatus. Once on the 
cell surface HLA-I bound peptide epitopes are presented to CD8+ T cells for recognition.  
 
In contrast peptides presented via the exogenous class II pathway are derived from 
extracellular proteins endocytosed and digested by the host cell. Not all cells express 
class II and process antigen in this way, but it is constitutively expressed in professional 
antigen cells including B cells, macrophages and dendritic cells, and inducible in other 
cells, such as activated epithelial cells, by the presence of IFNγ. As with class I, HLA class 
II molecules are assembled in the endoplasmic reticulum, however as binding of target 
peptide must occur in the late endosome, an invariant chain li, is bound in its place. The 
assembled HLA class II molecule is exported via the Golgi apparatus, and directed by li 
target sequence, fuses with the late endosome. Degradation of the invariant chain by 
cathepsins leaves a small CLIP fragment blocking the peptide binding groove. CLIP is in 
turn removed by class II like HLA-DM to enable peptide binding. The assembled peptide-
HLA-II complex is then transported to the cell surface for CD4+ T cell recognition.  
1.5 Research goals and study methods 
Despite the relative prevalence of EBV in the population, relatively little is known about 
the infective process. For example, while a number of envelope glycoproteins are known 
to be essential for entry and infection, other glycoproteins have undefined roles and it 
remains unclear whether they act during fusion, migration and processing of the virus. 
Additionally, while immune recognition of actively infected cells is well studied, little is 
known of early recognition of infected B cells by CD4+ or CD8+ T cells, or which epitopes 
are targeted by the immune system. In order to study the timeline of infection we will 
use confocal microscopy, with fluorescently labelled antibodies to envelope 
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glycoproteins, allowing us to track progress through the cell. Further, IFNγ assay of T 
cell recognition of virion-borne epitopes will be used to determine uptake, processing 
and presentation by infected primary B cells. Lastly, selective knockout of viral 
glycoproteins will be used to try and ascertain the role of these in the infection process. 
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2 Materials & Methods 
2.1 Media and Buffer Solutions 
Cells Hygromycin Type Vessel Adherence 
2089 20µl/10ml RPMI Epithelial 10cm dish Semi 
BZLF1 KO 20µl/10ml RPMI Epithelial 10cm dish Semi 
gp350 KO 20µl/10ml RPMI Epithelial 10cm dish Semi 
gp42 KO 20µl/10ml RPMI Epithelial 10cm dish Semi 
gp85 KO 20µl/10ml RPMI Epithelial 10cm dish Semi 
Table 3. Cell culture lines used, all 2089 derived. 
 
Coating buffer (10x stock) Sodium carbonate 1.36g 
Potassium bicarbonate 7.35g 
- Make up to 100ml H20  
- Adjust to pH9.2 1M HCl/1M NaOH  
Blocking buffer PBS 500mls 
Bovine serum albumin 5g 
Tween 250µl 
Wash buffer PBS 5L 
Tween 2.5ml 
Table 4. Solutions for IFNγ ELISA 
2.2 Antibodies 
Species Target Dilution Identifies   
Mouse gp42 1/500 Glycoprotein gp42   
Mouse gp110 1/500 Glycoprotein gp110   
Mouse gp350 1/500 Glycoprotein gp350   
Rat p18 1/500 Capsid protein   
Rabbit LAMP1 1/500 Late endosomes/lysosomes   
Rabbit Rab5 1/500 Early endosomes   
 IFNγ  IFNγ   
Table 5. Primary antibodies for immunofluorescence and ELISA 
 
Species Target Dilution Conjugation   
Goat anti-Rabbit 1/1000 Alexa fluor 594 Invitrogen  
Goat anti-Mouse 1/1000 Alexa fluor 488 Invitrogen  
Goat anti-Rat 1/1000 Alexa fluor 488 Invitrogen  
 IFNγ  Streptavidin   
Table 6. Secondary antibody conjugates for immunofluorescence and ELISA 
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2.3 PBMC separation from whole blood 
Blood was obtained from donations from healthy donors or from apheresis cones 
obtained from the NHSBT, Birmingham. Blood was diluted in an equal volume of PBS 
and layered on top of lymphoprep. Samples were centrifuged at 1800rpm for 30 
minutes at room temperature. The separated PBMC layer was removed, washed twice in 
50ml PBS at 1600 and 1200rpm and re-suspended in 10ml RPMI, 1% FCS. The total 
PBMC count was made and B cell numbers determined by assuming B cells account for 
5% of total PBMC. 
2.4 Isolation of B cells from PBMCs 
Primary resting B cells were isolated from total PBMC by magnetic bead separation 
using CD19 Dynabeads, according to manufacturer’s instructions. Briefly, B cells were 
incubated with 4 dynabeads at 4°C for 30 minutes, washed x 5 in RPMI, 1% FCS to 
ensure B cell purity, then the beads were removed by incubation with CD19 
detachabeads for 45 minutes at room temperature. 
2.5 Passage of virus-producing cell lines 
The virus-producing 293 cell lines were maintained on 10cm plates in RPMI, 10% FCS, 
1% glutamine, 1% Penicillin/streptomycin (full medium) and 50uM Hygromycin. Cells 
were passaged twice a week when approx. 80% confluent. Briefly, the cells were washed 
in PBS then were detached from the culture plates by incubation with 1ml trypsin at 
room temperature for 2 minutes. The trypsin was neutralized with RPMI, 10% FCS and a 
single cell suspension was passaged at 1 in 3 to fresh plates. 
2.6 Induction of lytic replication in virus producing 293 cells 
The 293 cells were grown to approx. 80% confluence on 10cm plates. The cells were 
removed from the plates by trypsinisation as above, then re-suspended in 28ml of fresh 
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full medium without hygromycin. This single cell suspension was plated onto 9 wells of 
two 6 well plates at 3ml per well and incubated at 37°C overnight. The following day, for 
each well of the 6 well plate, transfection mix was prepared: 100ul of OptiMEM was 
incubated with 6ul lipofectamine, 0.5ug BZLF1 (p509) and 0.5ug gp110 (pRA) 
expression plasmids for 20 minutes at room temperature. Following this incubation, the 
transfection mix was made up to 1ml with OptiMEM. All medium was removed from the 
293 cells and replaced with 1ml transfection mix, incubated at 37°C for 3 hours then 1ml 
of full medium added without hygromycin. The virus was harvested after 3 to 5 days of 
incubation at 37°C, when the virus supernatant was removed, centrifuged to remove 
cells and filtered with a 0.45um syringe filter. The virus was frozen at -80°C until use. 
2.7 Virus purification 
Intact, enveloped virus particles were purified by density ultra-centrifugation on an 
Optiprep gradient. Sixty per cent Optiprep was diluted to 30% in Optiprep diluent 
(0.85% w/v NaCl, 60mM Hepes-NaOH, pH 7.4) and 1ml was added to a 14ml Beckman 
centrifuge tube. Eleven ml of virus supernatant was layered on the Optiprep and tube 
pairs balanced for ultracentrifugation in an SW40 (swing) rotor at 20,000rpm for 2 
hours with max acceleration, slow deceleration to concentrate the virus on the Optiprep 
cushion. Following centrifugation, 10ml supernatant was removed and discarded, then 
the remaining 1ml concentrated virus and 1ml Optiprep cushion were mixed thoroughly 
to give a 15% solution of Optiprep. This was transferred to a 4.8ml Beckman 
ultracentrifuge tube, topped up with 15% Optiprep, balanced and the top sealed. The 
tubes were centrifuged in a vTi60.5 vertical rotor at 64,000rpm for 2 hours and 40 mins, 
4°C with max acceleration and slow deceleration. Following centrifugation, the purified 
concentrated virus band, visible as a white layer towards the bottom of the tube, was 
removed by needle aspiration in a 200ul volume. 
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2.8 Virus titre quantification 
Virus titre was quantified using quantitative PCR for the single copy EBV viral DNA 
polymerase gene. The concentrated virus was initially diluted 1 in 20 in DEPC water, 
then 10ul of diluted supernatant was incubated with 10ul of virus lysis buffer (1 x PCR 
buffer, 1% Triton-x-100, 0.1mg/ml proteinase K) at 55°C for 1 hour, followed by 95°C 
for 5 minutes to inactivate the proteinase K in the lysis solution. Five microliters of lysed 
virus was added to each PCR, with 1 x Taqman Universal PCR mastermix (Applied 
Biosystems), 12.5uM EBV DNA polymerase primers, 5pMol probe. Namalwa DNA (2 EBV 
genomes per cell) was used as the internal standard. 
2.9 EBV infection and Cytospins 
Aliquots of 1 x 106 primary resting B cells were initially incubated on ice with purified 
EBV at an MOI of 100, or uninfected, for 1 hour.  Unbound virus was washed off and the 
cells re-suspended in 1ml total medium then incubated at 37°C for 30, 60, 90 and 120 
minutes. Following each time point, the cells were washed in PBC and fixed in 1ml of 2% 
paraformaldehyde for 20 minutes at RT and 1 x 105 cells were subjected to cytospin 
onto poly-L-lysine-coated slides for 5 minutes at 1000rpm.  
2.10 Immunofluorescence 
Primary B cells and B cell lymphoblastoid cell lines were labelled with individual 
monoclonal antibodies (mAbs) or mAb combinations to minor capsid protein P18, 
gp350, early endosomes EA1 and late endosomes LAMP1. Antibodies were 
appropriately diluted (Table 5) in heat inactivated normal goat serum (HInGS). The cell 
spots generated by cytospin were isolated using a hydrophobic PAP pen. Slides were 
initially incubated in 0.1% glycine to reduce background staining caused by PFA fixation, 
then washed in PBS. The cells were permeabilised by incubation with 0.5% Triton-x-100 
at RT for 5 minutes, washed in PBS then incubated with antibodies for 1 hour at 37°C in 
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a humidified chamber. The cells were washed three times for 5 minutes in PBS in a wash 
bath and incubated with appropriately-diluted secondary antibodies (Table 6) at 37°C 
for 30 minutes. Finally, the slides were washed x 5 in PBS as above, then mounted in 
Vectashield + DAPI to counterstain the nucleus. 
2.11 Confocal microscopy 
Stained B cells were viewed by confocal microscopy (Leica). Areas of apparent co-
localisation were assessed by the confocal software and z-stack images taken of whole 
cells. Selected images were analysed to ImageJ software to assess co-localisation.  
2.12 T cell assay 
Primary B cells were isolated from lab donors and HLA matched to T cell clones 
targeting desired epitopes. Purified virus supernatant was added to target cells with 
500ul RPMI+10% FCS to allow for gas exchange in presence of OptiPrep and left to bind 
on ice. After 1 hour samples were removed from ice and spun down at 5000rpm 4 mins 
to remove virus and re-suspended in fresh media. Cells were then incubated at 37’c for 
required time-course. Optionally fixation was performed by re-suspending cells in PBS 
then fixing with 1% PFA 1ml for 10 minutes before quenching with 9ml 0.2M glycine. 
Cells were washed twice and re-suspended in RPMI+10% FCS. 
 
For each experiment protein standards were produced using known target peptides. 
Positive control was by lytic B95.8, with BZLF K/O LCL and primary B cells to confirm 
processing. Cells were re-suspended in 500ul RPMI+10% FCS and 1ul of each target 
peptide was added and incubated for 1 hour at 37’C. Pulses cells were then washed 
three times in RPMI+10% FCS then re-suspended at 100ul/target well. 
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Prepared cells were seeded to V-bottom plate at 5x104 B cells/well and 100ul/well. HLA 
matched T cell targets were seeded at 5000 T cells/well and left to incubate for required 
time. Resulting supernatants were harvested for IFNγ ELISA. 
2.13 IFNγ ELISA 
Maxisorp (Nunc) plates were coated with anti-human IFNγ stock antibody diluted in 
coating buffer with 50µl per well at a concentration of 0.75ug IFNγ/ml. Plates were left 
to block overnight at 4’c. The following day, antibody was flicked off and the plate 
blocked with blocking buffer at 200µl per well. A standard curve was prepared using 
stock IFNγ (1x10-3mg/ml) diluted at 4ul/2ml, giving 2000pg/ml, serially diluted to 
31.25pg/ml final. An additional blank (no IFNγ) was prepared. Plate was washed with 
washing buffer 6 times, and then standards and test supernatants added, as per plate 
plan, at 50µl/well. A second plate, at 1/10 dilution was prepared using 45µl wash buffer, 
with 5µl supernatant. Plate was incubated for 2 hours at room temperature, then flicked 
off into Virkon and washed a further 6 times in wash buffer. Secondary biotinylated anti-
IFNγ antibody was diluted in blocking buffer to 1/1333 dilution and added at 50µl/well 
to the plate. Plate was incubated at room temperature for 1 hour and then washed 6 
times in wash buffer.  
 
Extravidin peroxidise was diluted with blocking buffer 1/1000 and added at 50µl/well. 
Plate was incubated at room temperature for 30 minutes and then washed 10 times in 
wash buffer. 100µl of TMB substrate was added per well, left for 20 minutes to develop, 
and stopped with 1M HCl 100µl/well. Plate was read by spectrophotometer with 
absorbance 450nm and blank 655nm 
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3 Results 
3.1 Primary resting B cells are endocytically inactive 
It was first essential to determine the suitability of selected endosomal antibodies to 
visualise the endosomal pathway. Rab5 and EEA1 were selected as early endosomal 
markers, and Lamp1 as a late endosomal marker, and suitable antibodies to each of 
these were each titrated for confocal microscopy. Initial staining was performed on LCL 
cell lines which are known to be constitutively active, with uninfected primary B cells as 
a negative control for endosomes. The absence of endocytic activity in resting primary B 
cells, and relative abundance in constitutive LCLs was confirmed (Figure 3). 
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Figure 3. LCL and primary B cells with antibody staining for early (EEA1) and late (Lamp1) 
endocytic activity. Note the absence of endosomes in the primary B cells. 
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3.2 EBV infection up-regulates endocytosis in B cells  
With these confirmed early and late endosomal markers, it was now possible to study 
the process of viral entry via the endosomal pathway. As before, a number of viral 
proteins were assayed for effectiveness using LCLs, with abundant glycoprotein gp350 
and minor capsid antigen p18 providing consistent staining and subsequently used. 
Here, results showed a rapid increase in endocytic activity in primary B cells following 
binding and uptake of EBV visible at the 15 minute time-point (Figure 4).  
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Figure 4. Early and late endosomal staining in primary B cells 15 minutes post-binding with EBV. 
Note the increased endocytic activity following uptake of the virus.  
 
3.3 EBV proteins co-localise with early and late endosomes 
To study the progression of endocytosed virus co-localisation of EBV proteins with early 
and late endosomal markers was analysed by confocal microscopy at serial time-points 
from 0 to 2 hours. Co-localisation of viral proteins with cellular early endosomal 
markers was observed at 15 minutes – the first time-point post-binding (Figure 5 & 
Figure 6). Co-localisation with early endosomal markers continued to be observed out to 
the 30 minute time-point after which it declines rapidly. At the final 120 minute time-
point little to no co-localisation of viral proteins with early endosomal markers was 
 21 
observed. In contrast, co-localisation of viral proteins with late endosomal markers was 
first observed from the 60 minute time-point (Figure 8 & Figure 8), with the exception 
of single image appearing to show small levels of co-localisation in a cell at 15 minutes. 
From 60 minutes onwards co-localisation continued with late endosomal marker Lamp1 
out to the final 120minute time-point.  Interestingly, we also observed that although the 
surface of primary B cells were frequently bound by multiple virions, relatively few 
virus particles were actually endocytosed – persisting until the 2 hour time-point with 
no apparent further uptake. 
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Figure 5. Early Endosomal Localisation (gp350/EEA1). Beginning of co-localisation of viral proteins and early endosomes is  
observed frequently from the earliest time-point at 15 minutes and reaching a peak at just 30 minutes post-binding. 
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Figure 6. Early Endosomal Localisation (p18/EEA1). Beginning of co-localisation of viral proteins and early endosomes is  
observed frequently from the earliest time-point at 15 minutes and reaching a peak at just 30 minutes post-binding. 
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Figure 7. Late Endosomal Localisation (gp350/Lamp1).  Co-localisation of viral proteins and late endosomal compartments 
peaks at the 60 minute time-point from binding, although in rare cases co-localisation with late endosomes is seen as early as 15 minutes. 
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Figure 8. Late Endosomal Localisation (p18/Lamp1).  Co-localisation of viral proteins and late endosomal compartments 
peaks at the 60 minute time-point from binding, although in rare cases co-localisation with late endosomes is seen as early as 15 minutes. 
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3.4 Functional avidity of EBV-specific CD4+ T cell clones 
In order to study CD4+ T cell recognition of EBV-infected cells in the early hours post-
infection a panel of available CD4+ T cells specific for various EBV antigens was used. 
Production of IFNγ observed during T cell recognition of cognate antigen is determined 
by both the quantity of peptide presented via HLA class II and the avidity of the T cell 
clone for the target epitope. As levels of presented peptide increase the likelihood of T 
cell recognition is increased, however in order to compare results between clones of 
different specificities the relative avidities were assessed. Thus, in future experiments 
variations in T cell response may be accurately accredited to variations in T cell avidity. 
 
A panel of T cell clones selected for these experiments were assayed with known HLA-
matched 1’B cells and known peptide concentrations from 1x10-11mg/ml to 1x10-5 
mg/ml. Response curves were plotted and graphed (Figure 9) and EC50 were read 
coinciding with the straight logarithmic region of the curve. These EC50 values were 
used to compare each clone (Figure 10) demonstrating relatively similar functional 
avidities of T cell clones within groupings as follows: LDL & LEK, FLD & DNEc70 & VKF 
& PAQ and DNEc28 & VKL.  
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Figure 9. Relative IFNγ responses by T cell clones, matched concentrations of target epitopes. 
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Figure 10. EC50 values of IFNγ response by T cell clones, indicating relative avidity of the clones. 
Groups of clones LDL/LEK, FLD/DNEc70/VKF/PAQ and DNEc28/VKL have similar avidities. 
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Figure 11. T cell IFNγ control assay. Performed in conjunction with each experiment to confirm 
ability of B cells to present target epitope and T cells to respond. Here, LDL specific CD4 T cell 
recognition of target viral peptide (gp350) is functional in both BZLF K/O LCLs and primary B 
cells with response activation detectable by IFNγ.  
 
3.5 Antigen presentation early after EBV infection 
Initial experiments were designed to assess the ability of infected B cells to present viral 
envelope proteins delivered as components of the incoming virion. BZLF1 knockout 
LCLs – with no lytic protein expression – were used as a control, as these cells are 
activated and efficient antigen presenters. 
 
Infection of BZLF1 knockout LCLs is associated with rapid processing of viral coat 
antigens and detection of presented antigen on the surface via HLA class II within 3 
hours post-binding. Presentation peaked following 5 hour incubation and reached a 
plateau shortly after. In contrast T cell recognition of infected primary B cells was not 
seen up to 7 hours post-binding, but could be detected after 18 hours if the target cells 
were left unfixed before addition to the assay (Figure 11). 
 
Fixation reduces recognition of presented antigens and explains the disparity between 
the 7 hour and 18 hour time-points in LCLs. Importantly, a T cell response to antigen 
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presentation via primary B cells is observed indicating that the minimum timescale for 
response lies somewhere between the 7 and 18 hour time-points. Importantly, secretion 
of IFNγ requires de novo transcription and total time from T cell antigen recognition to 
IFNγ production is approximately 8 hours. Therefore T cell detection of antigen 
presented via the B cells in the unfixed 18hr time-points must occur before 10 hours 
post binding to allow for IFNγ production. 
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Figure 12. Antigen processing and presentation of LDL/gp350 epitope by primary B cells and 
BZLF knockout LCLs. Presentation in LCLs is rapid with first indication at the 3 hour time-point 
reaching peak at 5 hours with plateau following. In contrast primary B cells do not present before 
7 hours, but have by 18 hours post-binding. Note that samples taken to 18 hours were unfixed.  
 
3.6 EBV infected primary B cells present virion antigens within 7hrs 
We therefore repeated the infection assay over an extended 12 hour timescale (Figure 
13).  This confirmed previous results showing T cell recognition of infected LCLs from 3 
hours post-binding and additionally demonstrated recognition of primary B cells from 7 
hours post binding by both gp350 and gp85 specific CD4+ T cells. As previous results 
showed no recognition up to the 7 hour time-points for this experiment were selected to 
cover post-7 hours more completely and so no 6 hour time-point data is available. Taken 
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together with previous results it is suggested that virion antigens can be presented to 
CD4+ T cells near to this 7 hour time-point post-binding.  
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Figure 13. Antigen processing and presentation of LDL and LEK epitopes by primary B cells and 
BZLF knockout LCLs over 12 hour time-course. Presentation in primary B cells occurs at 7 hours. 
 
 
3.7 Viral entry is required for early CD4+ T cell recognition 
In order to establish whether T cell responses to virus peptides required receptor-
mediated uptake 1’B cells were infected in parallel with knockout gp350 virus and wild 
type virus at equivalent MOI of 100.  In both LCL and primary B cells presentation of 
viral peptides (gp85, gp350) was observed in the wild type virus. However, no T cell 
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responses were observed to LCL or primary B cells infected with knockout virus lacking 
cell binding glycoprotein gp350 (Figure 14).  
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Figure 14. Responses of LEK/LDL specific CD4+ T cells to gp85 and gp350. Responses are seen to 
peptide, but absent to infection with gp350 knockout  
 
3.8 Viral antigen requires intra-cellular processing for CD4+ T cell 
recognition 
Surface HLA class II molecules are capable of binding and pseudo-presenting peptide 
from the environment around the cell. In order to establish that the T cell recognition 
detected is of endosomally processed antigen, an assay was performed in which B and 
LCL cells were fixed before virus binding. Additionally an equal number of cells were 
incubated with free peptide solution to confirm that fixation did not impair the capacity 
of the surface HLA to present peptide. Neither the fixed B cells nor the LCLs exposed to 
whole virus were able to generate a T cell response (Figure 15), indicating that 
internalisation of virus is required for the observed T cell responses. Further, this 
experiment excludes the possibility of free peptide in the virus preparation being 
responsible for T cell recognition seen earlier. 
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Figure 15. Responses of LEK/LDL specific CD4+ T cells to gp85 and gp350 respectively. 
Responses are seen to peptide, but absent in fixed cells 
 
3.9 T cell responses are only against capsid antigens 
We were interested to see whether virus-borne antigen could be similarly processed for 
CD8+ T cell recognition by cross-presentation. Further we wanted to confirm that only 
virus-borne antigen is processed for CD4+ T cell recognition at these early states post-
infection, not antigens that require transcription from the EBV genome. In order to 
further clarify the routes for host recognition of active infection, it was necessary to 
exclude the possibility of recognition of endocytosed viral antigen via the HLA class I 
pathway. If antigen from endocytosed virus were presented in this way it would provide 
a mechanism for recognition of infected B cells by CD8+ T cells prior to active lytic 
infection. Primary B cells and BZLF K/O LCLs were incubated with wild type virus for 12 
hours post-binding. Infected cells were assayed with a range of T cell clones specific for 
a number of viral proteins, both capsid-borne and proteins requiring transcription from 
the incoming virus genome.  In addition a set of peptide controls were performed to 
confirm T cell sensitivity to targets.  
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Responses were only observed to virion borne target epitopes, specifically LDL (gp350) 
and LEK (gp85) as previously demonstrated (Figure 16). No CD4+ T cell responses were 
shown to any immediate early, early or latent proteins that are not components of the 
virus particle. Additionally, no CD8+ responses were observed to virus-borne 
glycoprotein gp110 indicating that presentation of endocytosed virus does not occur via 
the HLA class I pathway. 
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Figure 16. CD4+ & CD8+ T cell responses to early, late and lytic antigens. Responses are only seen 
to LDL and LEK epitopes from structural virion proteins, not early or immediate early proteins. 
Further, no response is seen in CD8+ T cells to virion antigen gp110. 
 34 
3.10 Recognition of glycoprotein knockout virus-infected B cells 
To assess the contribution of viral membrane glycoproteins to binding, internalisation, 
fusion and processing of virus by the host cell, a number of knockout viruses were used 
in comparative infection assays over a range of MOIs. A brief outline of each 
glycoprotein knockout is given below, for a full list see Table 2. 
 
 gp350/220 – Binds CR2/CD21, initial attachment and entry 
 gp85, gp110, gp42 – Form complex, with gp42 binding HLA class II in the 
endosomal pathway triggering fusion and release of the capsid into the 
cytosol. May also bind HLA class II on the surface, with possible role in entry. 
3.10.1 Recognition of knockout virus-infected B cells by gp350-specific CD4+ T cells 
In the first experiment T cell clones specific for gp350 epitope LDL were used to assay 
presentation of viral antigen following infection with various knockout viruses. As the 
assay target was for gp350 the absence of a response in the gp350 knockout virus-
infected cells is expected, and confirmatory of the status of the knockout virus. The 
strongest recognition was seen against wild type virus-infected B cells, from 
physiological MOI of 1 upwards. Knockout viruses gp85 gp42 show much reduced T cell 
recognition at low MOIs but with increasing recognition at higher levels (Figure 17). 
Additionally, while gp42 and gp85 knockout viruses share similar profiles at MOIs of 1 
and 5, recognition of Δgp85 virus relatively increased from an MOI of 50 and above.   
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Figure 17. IFNγ responses by CD4+ T clones targeting gp350 epitopes. Complete absence on 
response by LDL (gp350) specific T cells to Δgp350 virus is observed confirming knockout. At 
physiological MOIs both Δgp42 and Δgp85 result in similar reduced recognition profile compared 
to wild type. At higher MOIs reduction in Δgp85 is overcome. 
 
3.10.2 Recognition of knockout virus-infected B cells by gp85-specific CD4+ T cells 
As with results for gp350 epitope LDL, recognition of gp85 by the LEK-specific CD4+ T 
cells is notably higher in wild type virus-infected B cells, albeit with recognition first 
observed from an MOI of 5 or more (Figure 18). However, gp85 specific T cells show 
little to no recognition of Δgp42 or Δgp350, with background activation observed in the 
case of Δgp85 forming the baseline. 
 
 36 
LEK (gp85)
1 10 100
-500
0
500
1000
1500
WT
gp42
gp85
gp350
0
MOI
IF
N
  
p
g
/m
l
 
Figure 18. IFNγ responses by CD4+ T clones targeting gp85 epitopes. All knockout viruses exhibit 
similar profile of little or no recognition by gp85 specific T cells, probably reflecting relative 
quantities of gp85 in the virion and presentation efficiency. 
 
3.10.3 Recognition of knockout virus-infected B cells by gp110-specific CD4+ T cells 
In both of the previous assays T cell target epitopes were within one of the antigens 
knocked out in one of the viruses used. Here the target epitope DNE gp110 is available 
to be presented in each of the knockout viruses. Two clones c28 and c70 targeting the 
epitope were used due to low levels of recognition observed in the T cell avidity assay 
(Figure 19). As previous results show, recognition of peptides from the wild type assay 
is detectable from an MOI of 1 (c70). Recognition in Δgp85 virus was only slightly 
hindered achieving similar levels as that observed in the wild type by MOI of 100. As 
gp42’s established role is as a co-partner with gp85 in the fusion complex, a similar 
pattern for knockout of these two proteins was expected. However, interestingly Δgp42 
and Δgp350 instead show strikingly similar recognition profiles, suggesting that uptake 
and processing is similar between these two knockouts. At physiological levels of 1+5 
MOI the K/O viruses have similar effects. Higher T cell recognition seen at larger MOIs 
may be due to non-specific endocytosis. 
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Figure 19. IFNγ responses by CD4+ T clones targeting gp110 epitopes. Note that none of the 
knockout viruses are for gp110, therefore responses directly reflect uptake and presentation of 
each virus variant by the primary B cells. Both Δgp42 and Δgp350 share similar profiles, 
demonstrating uptake at non-physiological MOIs. As previously Δgp85 mimics other knockouts 
at physiological MOIs but recovers as virus quantity increases. 
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4 Discussion 
Epstein-Barr virus is an endemic virus1 that has been implicated in a variety of 
lymphomas and solid tumours human tumours, including Hodgkin’s lymphoma (HL) 
and nasopharyngeal carcinoma3. Despite this prevalence, relatively little is known about 
the early stages of virus infection or the role of virion-borne glycoproteins in uptake and 
processing. Additionally, responses in primary and long-term infection have been well 
characterised24,20 the extent of CD4+ and CD8+ T cell recognition in the early hours 
following infection of resting B cells is not yet known. 
4.1 Endocytosis and trafficking of EBV in primary B cells 
The process of endocytosis and trafficking of EBV in primary infected B cells is poorly 
characterised. Here we have used confocal microscopy to obtain an overview of EBV 
entry and develop representative timeline of EBV uptake and trafficking within the 
infected cell and provide insights into the process of endosomal migration. 
4.1.1 Endocytosis is rapid but rare and restricted in primary B cells 
Resting primary B cells are endocytically inactive under normal conditions. Here we 
show that EBV binding induces endocytosis in these cells within 15 minutes of initial 
binding, with subsequent co-localisation with early and late endosomes by 30 minutes 
and 1 hour respectively. Previous electron microscopy studies47 suggest that the virus is 
released from early endosomes following acidification by 15 minutes post binding, and 
capsids were observed at the nucleus 60 minutes following infection. However, we have 
observed virus envelope (gp350) and virus capsid (p18) in late endosomes. We propose 
that during fusion and release of the capsid, membrane glycoproteins remain in the 
internal wall of the endosome. We have also demonstrated that delivery of EBV genomes 
to the B cell nucleus is extremely inefficient with the majority of virus retained on the B 
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cell surface, however, the presence virus capsid in late endosomes therefore confirms 
that fusion is also not guaranteed. We propose that as super-infection of transformed B 
cells is possible48 endocytosis and uptake may follow a bi-phasic pattern, with post-
uptake inhibition driven by loss of actin cytoskeleton required for the endocytic process.  
4.1.2 Endocytosed virus is successfully trafficked endosomally 
Trafficking through the early endosomal compartment is a rapid process, and 
subsequent entry to the late endosomal compartment was observed from 60 minutes 
post-binding, suggesting efficient endosomal processing particularly for a resting 
primary B cell. The late-endosomal localisation of EBV in infected primary B cells 
remained until 2 hours post-binding, although some hints of fusion were seen.   
Quantification was difficult due to the low quantity of virus entering the primary resting 
B cell. We can increase sensitivity by generating a recombinant virus expressing 
fluorescently-labelled structural protein or glycoprotein such as gp350. If coupled with 
real-time microscopy this could also overcome the technical limitation of using time 
points in a dynamic system. 
4.2 Virion-derived antigens mediate T cell recognition of newly 
infected B cells 
The ability of T cells to recognise and kill newly-infected cells is central to effective 
clearance of a replicating virus in vivo by interrupting the process of replication and 
spread within the host. Characterising which T cells are able to function in this capacity 
in the context of EBV has important implications for both vaccine development and 
adoptive transfer T cell therapy for EBV malignancies49.  
 
As previously described, EBV infects B cells that constitutively express MHC class II and 
EBV-specific CD4+ T cells that directly recognise EBV-infected B cells are well 
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known25,50. As EBV infects through endosomal entry the cell is perfectly positioned to 
process and present the invading virion antigen for presentation by HLA class II in 
immediate stages of infection. Structural antigen-specific CD4+ T cells may be the first 
cells of the immune system able to recognise infected cells. Importantly, this processing 
and presentation would be independent of virus transcription or replication, and 
performed on the intact virus particle prior to un-coating. As such no viral immune 
evasion genes would be able to be transcribed and no capsid-borne host regulators can 
be employed – the virus is at its most vulnerable to any defences the host may mount. 
Such recognition has been demonstrated previously in a limited study50, but only 24 
hours post infection, Therefore, we here study CD4+ and CD8+ T cell recognition 
immediately post-infection. 
4.2.1 Response is to HLA-II processed competent infective virus 
We first excluded other potential routes for viral antigen uptake and subsequent 
presentation, demonstrating through gp350 knockout and fixed cells that presentation 
of virion-borne antigens to CD4+ T cells was dependent on receptor-mediate virus entry 
and did not occur via non-specific processing of antigen. Recognition of structural viral 
antigens presented via the HLA class II pathway to HLA matched specific CD4+ T cells 
was rapid following initial binding. CD4+ T cell recognition of viral epitopes presented 
by infected endocytically active LCLs occurred at just 3 hours post-binding. In dormant 
1°B cells initial T cell responses were observed at 7 hours post-infection, still 
remarkably early. In conjunction with previous results a broad timeline may be 
established for the uptake and presentation of viral antigen as described in Table 7. 
Interestingly, after the 8 hour time-point no further increase in CD4+ T cell IFNγ 
response is seen, adding weight to earlier observations of phasic entry. 
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Min Process 
0 Endocytosis 
15 Early Endosome 
60 Late Endosomes & Lysosomes 
480 Presentation of HLA class II loaded antigen at 1° B cell surface 
Table 7. Putative timeline of endocytosis and endosomal processing in 1° B cells 
 
Importantly, this demonstrates that viral structural-antigen T cell clones are able to 
recognise and respond to infected primary B cells from 3 hours post-binding of the virus 
particle on the surface of the cell. Given recent demonstrations that some lytic antigen-
specific CD4+ T cells can directly kill antigen-expressing B cells in vitro50,21 this suggest a 
role for structural antigen-specific CD4+ T cells in the early phase of response to de novo 
infection of primary B cells. 
 
However, CD8+ T cells also play a key role in the targeted killing of virally infected cells. 
In order to clarify the mechanism of early host-recognition, we considered the 
possibility of both cross-presentation of endocytosed post-fusion viral antigen via the 
HLA class I pathway. Here we have successfully demonstrated that envelope antigen is 
not processed for MHC class I presentation. However, the possibility remained that 
membrane-bound envelope antigens may be excluded by remaining internal to the 
endosomal compartment following fusion. However, unpublished data colleagues have 
shown that recognition of other viral antigens including minor capsid p18 requires gene 
transcription and takes several days to occur.  
4.2.2 No responses to immediate-early or early genes 
Immune recognition of viral antigens is a central plank of immune responses to 
infection. In order to minimise their exposure, and therefore limit the ability of the host 
to mount an effective immune response, many viruses employ a variety of host evasion 
and control mechanisms51. EBV itself contains a number of viral immune evasion 
proteins including two that act on the HLA class II pathway BZLF1 and gp4252. However, 
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production of these evasion products is dependent on transcription of the viral genome. 
The earlier a virus is able to initiate transcription of these products the higher the 
opportunity for survival.  
 
Using an assay of epitopes to immediate early, early and lytic viral gene products, we 
confirmed that no such viral replication was taking place with experimental timescales. 
Only structural viral proteins gp85, gp110 and gp350 were detectable by CD4+ T cell 
assay by 12 hours post-binding suggesting CD4+ T cell recognition of structural virion 
antigens is the key mechanism for recognition of early infected B cells. Further, it is 
proposed that CD4+ T cell mediated targeted cell killing may have a key role in control 
of early or reactivating infections in vivo.  
4.3 The role of EBV glycoproteins in viral entry 
Envelope glycoproteins play a central role in the EBV infectious process and individual 
roles of some glycoproteins are well characterised. The initial attachment of EBV to the 
B cell is mediated via the high affinity interaction between gp350/220 and CR2 
(CD21)27. Subsequent interaction between gp42 and HLA class II, followed by the 
recruitment of gp85 and gp25 forms a tripartite complex. Either interaction of gp350 
with CD21, interaction of gp42 with HLA class II or interaction of gp25/gp85 with an as 
yet unknown fusion receptor induces endocytosis39. Our experiments using individual 
glycoprotein knockouts and the highly-sensitive T cell recognition assays have provided 
further insights as to which interactions induce endocytosis. 
4.3.1 Knockout of gp350 inhibits virus binding 
As previously described29, we confirmed that loss of gp350 from the viral envelope 
prevents viral uptake at physiological multiplicity of infection (MOI) but that low level 
uptake is present when MOI reaches non-physiological levels (50+) as detected by CD4+ 
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T cells specific to gp110 epitopes. Recognition of gp85 was absent event at these MOI 
levels, perhaps related to relative quantities of glycoproteins in the viral envelope. 
However, when taken in the context of the strong response observed in wild type assays 
at an MOI of one, uptake in the absence of gp350 must be exceptionally low, confirming 
its key role in specific uptake. 
 
It has been suggested that non-specific uptake may occur via minor ligands and 
constitutive endocytic activity in the target cells29, however our earlier confocal 
microscopy confirmed that resting primary B cells are endocytically inactive prior to 
infection, suggesting that some trigger or uptake mechanism may be required. Low-
affinity binding of alternate glycoproteins is one such possibility, e.g. gp42 binds MHC 
class II in the endosomal pathway39 and a similar interaction may provide an attachment 
on the surface of the cell. Such alternative routes for entry may have implications for 
rare in vivo infection of cells of non-B non-epithelial lineage implicated in T cell 
lymphomas8, therefore further characterisation is essential. 
4.3.2 Knockout gp42 mimics gp350; suggested role for gp42 in entry 
The fusion complex of which gp85 is a part interacts with gp42 to enable binding to HLA 
class II. Therefore, it was expected that knockout of gp42 would produce similar results 
to those seen for gp85. However, knockout of gp42 resulted in an assay profile 
mimicking that seen for gp350 across all MOIs – including a complete absence of 
recognition at physiological levels. As previously described gp350 binds CR2 on the cell 
surface and gp42 is known to interact with HLA class II46. Therefore, these results 
strongly suggest that gp42 is essential to trigger endocytosis of bound virus – although 
this must be confirmed by confocal microscopy.  
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4.3.3 Knockout of gp85 decreases recognition; similar to gp42 
As part of the gp45gp25gp85 complex gp85 has a central role in the process of 
endosomal fusion and loss is associated with a failure to infect41 either by defects in 
uptake or fusion. If defects in uptake predominate, knockout was expected to be 
associated with a reduction in subsequent recognition by CD4+ T cells. Conversely, if 
knockout of gp85 inhibits fusion, it was expected that levels of recognition would be 
increased due endocytosed virus remaining in the endosomal compartment for 
processing and presentation. In fact, our experiments showed a decrease in recognition 
of viral peptides following gp85 knockout, when compared to that of wild type, similarly 
to gp42 and gp350 knockout at physiological MOIs. 
 
This strongly suggests a role for gp85, likely as a component of the tripartite complex, in 
induction of endocytosis. As the ligand for gp85 is currently unknown, further work is 
needed to characterise the role of this interaction in uptake. However, the possibility of 
inside-out signalling via an integrin or other molecule, offers an attractive solution to 
the mechanism of both induced endocytosis and perhaps biphasic entry.  
4.4 Conclusions 
A number of outstanding questions remain in our understanding of the role of 
glycoproteins in EBV uptake by primary B cells. However, we have demonstrated that 
uptake is a rapid, yet selective process, restricted potentially by not just gp350 but other 
glycoproteins in the virus envelope in as yet unknown interactions. Endocytosis results 
in rapid and profound up-regulation of endocytic activity in resting primary B cells, yet 
uptake appears to follow a phasic pattern, with little or no secondary uptake observed 
during the first 2 hours. Trafficking of endocytosed virus is rapid, reaching the late 
endosomal compartment within 1 hour.  Antigen processing, loading onto HLA class II 
and presentation at the cells surface occurs within 8 hours of the virus binding on the 
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cell surface. Such early-warning of cellular infection, well in advance of viral genome 
transcription, provides an attractive target for immunotherapy. 
 
Fusion within the endosome is far more complex than the gp42/25/85 system outlined 
here. It has been shown that gp110 is required for endosomal exit53, and viral tegument 
protein BNRF1 also has a role with loss resulting in a 20-fold reduction in escape54. In all 
EBV has one of the most complex systems of entry and escape from the endocytic 
pathway. Therefore to pick this apart, we need several systems ranging from real time 
confocal microscopy and fluorescently-labelled virus particles, electron microscopy, 
antibody generation to identify nascent and fusion-competent glycoproteins and a read-
out such as the exquisitely sensitive T cells. Until we understand exactly how the virus 
enters the individual cell types and the role of the viral glycoproteins, we cannot hope to 
generate an effective vaccine. In patients with EBV lymphoproliferation, these studies 
will further help us to understand how to best target CD4+ T cell immunotherapy. 
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Abstract 
Macrophages have a wide range of immunological and non-immunological functions in 
the host, ranging from clearance of apoptotic cells, tissue remodelling, and release of pro 
and anti-inflammatory mediators at site of tissue damage or infection. Within these 
wide-ranging functions however, subsets of macrophages show unique phenotypic 
adaptations to their role. Studies on monocyte-derived cell lines have shown that these 
phenotypic differences are matched by underlying metabolic signatures, with the 
potential to have profound effects on cell capabilities. In order to determine whether 
differentiated macrophages displayed similar profound metabolic profiles, and whether 
these differences affect function, we differentiated primary blood monocytes under a 
range of culture oxygenation conditions. Initial results show significant differences in 
the metabolic profiles of M1 vs. M2 macrophages undergoing differentiation, with M1s 
displaying much reduced lactate levels, and corresponding increases in glucose 
suggestive of  gluconeogenesis via putative PFKFB3 (fructose-1,6-bisphosphatase) 
activity. M1s were demonstrated to be constitutively active under reperfusion 
conditions, with no corresponding metabolic changes following LPS stimulation. M2s, in 
contrast, showed an expected hypoxia profile of increased lactate levels under 
differentiation, and remained inactive in reperfusion conditions,  however production of 
IL-10 following LPS stimulation was shown to be significantly reduced in hypoxic 
conditions. A model of permissive inflammation during M1 infiltration and under 
hypoxia is suggested, with reperfusion and reduced recruitment driving resolution in 
normal tissues. However, in persistently hypoxic tissues or regions of aberrant 
recruitment and proliferation, the potential exists for differentiating macrophages to 
drive and maintain a chronic inflammatory state.  
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1 Introduction 
1.1 Macrophages 
Macrophages are monocyte lineage derived white blood cells, with a role in both non-
specific innate immune responses and the initiation of adaptive immunity. In the tissues 
macrophages have an important role in clearance of pathogens and cellular debris, 
antigen presentation and immune stimulation and regulation1.  
 
Bone marrow Peripheral blood
HSC GM-CFU M-CFU Monoblast Pro-monocyte Inflammatory Resident
 
Figure 1. Differentiation and migration of monocytes from bone marrow to the circulation. 
Adapted from ‘Exploring the full spectrum of macrophage activation’ D Mosser, J. Edwards. Nat. 
Rev. Imm. 2008.2 
 
Production of PBMCs occurs in the bone marrow from a common myeloid progenitor 
shared with neutrophils and dendritic cells1. Myeloid progenitor cells sequentially 
differentiate to monoblasts, pro-monocytes, and monocytes. Matured monocytes are 
then released into the peripheral blood as non-dividing cells, representing about 5-10% 
of peripheral blood leukocytes3, and circulating for an average of 3 days before 
ultimately migrating into the tissues4. There is debate about whether sub-populations of 
macrophages are predefined, or whether subsequent differentiation during circulation 
drives outcome. However, evidence from animal models has demonstrated that 
migration can occur throughout the differentiation continuum, and suggests that the 
resulting phenotype may be determined by timing5,6. 
 
In humans two broad populations are identified in the circulation, termed classical 
monocytes and non-classical monocytes6. The former are CD14hi CD16- and migrate 
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from the blood shortly after maturation, differentiating to tissue-resident macrophages 
or dendritic cells. The latter are CD14+ CD16+ and remain resident in the blood, with a 
putative role in maintenance of the endothelial lining of blood vessels, and as a reserve 
for tissue resident macrophages2,7,8. Post-migration monocytes undergo further 
differentiation in response local factors, with GM-CSF in the presence of IL-4 promoting 
dendritic cell formation and GM-CSF/M-CSF driving differentiation to macrophages9. 
 
Blood Tissues
Resident Macrophage
• Langherhans cells (skin)
• Kuppfer cells (liver)
• Osteoclasts (bone)
• Microglia (CNS)
Recruited Macrophage
• Classically activated (M1)
• Alternatively activated (M2)
Monocytes
 
Figure 2. Differentiation and migration of peripheral monocytes to resident tissue macrophages 
and recruited M1/M2 macrophage populations. ‘Alternative activation of macrophages’. Siamon 
Gordon, Nat. Rev. Imm. 200310. 
 
1.2 Macrophage differentiation and activation 
Mature populations of recruited macrophages are grouped under two broad 
classifications defined by phenotypic differences and stimulating cytokines. M1 
macrophages, also referred to as ‘classically activated’ are effector cells, with enhanced 
microbicidal and tumoricidal effects and secrete pro-inflammatory cytokines11,2. M1 
macrophages cell-mediated immune responses in the presence of IFNy and TNF with 
immediate responses are driven by innate NK cells which produce transient high levels 
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of IFNy in response to stress and infection, while sustained responses follow production 
of IFNy by T helper 1 (Th1 cells) in an antigen specific manner. However, activated 
macrophages are also capable of non-specific killing in an antigen-independent manner - 
and indeed increases antigen availability to local antigen presenting cells.  
 
M2, or ‘alternatively activated’, macrophages are a less defined family of macrophages, 
broadly covering any macrophage subtype not stimulated by IFNy but by Th2 type 
cytokines IL-4 and IL-1310. These cells have a role in humoral immunity, repair and 
vascularisation12 in damaged tissues, and are therefore associated with the resolution of 
the inflammatory process. IL-4 stimulates arginase activity in alternatively activated 
macrophages, driving conversion of arginine to ornithine, a key pre-cursor in the 
production of extracellular matrix13. Interestingly, it has recently been shown that the 
M2 macrophages are able to undergo replication in the tissues, rather than solely 
migrating from the circulation14, which may have implications in chronic inflammation. 
1.3 Macrophages in the inflammatory site 
Differentiated macrophages have important roles in both homoeostasis and control of 
active infections. Splenic macrophages phagocytose defective erythrocytes, clearing 
approximately 2 x 1011 erythrocytes from the blood each day, recycling 3kg of 
haemoglobin per year2. During tissue remodeling, macrophages are central to the 
clearance of cells that have undergone apoptosis in the absence of any immune 
stimulation, via scavenger receptors for phosphatidlyl serine, thrombospondin, 
integrins and complement15. Therefore, the major functions of macrophages are 
performed in the absence of immune stimulation and without subsequent activation. 
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Figure 3. An example inflammatory network from the rheumatoid joint, showing inflammatory 
and anti-inflammatory cytokine pathways between M1 macrophages, fibroblasts and T cells. 
Adapted from ‘Evolving concepts of rheumatoid arthritis, Firestein GS. Nature 200316 
 
In contrast, necrosis following trauma or infection results in cellular debris high in heat-
shock proteins, nuclear proteins, histones and DNA, together with cleaved extracellular 
matrix components17. Subsequent phagocytosis by tissue resident macrophages triggers 
physiological changes, including surface marker proteins and production of cytokines 
and pro-inflammatory mediators2. Surface TLRs, intracellular PRRs and IL1R on 
macrophages identify and stimulate responses to danger signals in the surrounding 
environment, mediated via myeloid differentiation primary-response gene 88 
(MyD88)18. It has been demonstrated that these responses are present in the absence of 
adaptive immune co-stimulation19. Responses to innate immune stimulation are 
typically broad but transient, with responses to adaptive stimulation result in more 
focused and prolonged alterations in macrophage physiology. Macrophages additionally 
produce several factors to auto-regulate their own physiology. 
 
Macrophages phagocytose pathogen and cellular debris and presenting foreign antigen 
to helper T cells via MHC class II to trigger appropriate and specific activation and B cell 
antibody production. Phagocytosis simultaneously triggers macrophage release of pro-
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inflammatory cytokines, central to the recruitment of other immune cells to the site of 
infection or damage. Activated effector T cells can in turn activate macrophages. 
Differentiation of immune cells is associated with profound changes in metabolism. For 
example, T-cell glycolysis is enhanced 6-fold 2 hours following stimulation, and 15-fold 
46 hours later20. Activation of naïve CD8+ T cells to effector cells induces up-regulation 
of glycolytic enzyme genes. In turn surrounding environmental metabolic conditions 
may affect immune cell function, with tumour cell derived lactate supressing 
proliferation and activation of CD8+ T cells21. Likewise, macrophage differentiation is 
associated with profound changes in cellular metabolism. Similarly, environmental 
conditions may in turn affect macrophage function. 
 
Tissue injury results in the recruitment of blood monocytes to the tissues and 
subsequent differentiation, and proliferation, depending on tissue conditions 
encountered. An initial influx of inflammatory-phenotype M1 macrophages is associated 
with tissue remodeling and pathogen/particulate phagocytosis. Later, injury-associated 
hypoxia, anaerobic respiration and resulting high lactate levels drives M2 macrophage 
pro-angiogenic responses via release of vascular endothelial growth factor (VEGF) in the 
surrounding tissues. Resident fibroblasts are induced to produce collagen. Resulting 
reperfusion and a return to tissue integrity drives a reduction in macrophage numbers 
to normal tissue-resident levels.  
1.4 Hypoxia in the inflammatory site 
Inflammatory sites are by their nature hypoxic, and such hypoxic sites are a common 
feature of a number of inflammatory diseases including the synovium of arthritic joins, 
wounds, bacterial infections and malignant tumours22. Local hypoxia develops as the 
result of either blood vessel occlusion by inflamed tissues, or when existing supply is 
insufficient for infiltrating or proliferating inflammatory cells. Normal tissue structures 
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additionally lend themselves to hypoxia, where they are poorly perfused, such as the 
synovium or eye. Metabolomic analysis of eye fluids from uveitis patients has shown 
increased levels of oxaloacetate and urea, likely derived from anaerobic respiration by 
locally activate macrophages23,24. Such metabolites may be indicative of macrophage 
upregulation of ascorbate transporters25 reflecting their need to function in 
inflammatory milieu. However, it is worth noting that not all macrophages are pro-
inflammatory, and therefore the presence alone is not indicative of role in disease.  
 
While macrophages are present throughout the tissues of the body, a tendency to 
accumulate in such areas of hypoxia is suggestive of a role for hypoxic conditions to 
drive macrophage residence and perhaps activation. Recent studies have shown just 
such a response, with wide variety of gene expression alterations observed in 
macrophages exposed to hypoxic conditions. Exposure of macrophages to hypoxic 
conditions is associated with upregulation of a whole gamut of proinflammatory IL-126, 
IL-627, IFN-y28, TNFa29. Conversely it is also associated with upregulation of 
immunosuppressive genes including PGE230, IL-1028, and downregulation of antigen-
presenting CD8031. Interestingly, additional angiogenic activity via the upregulation of 
VEGF and PGDFB29 suggests a role in both tumor survival and synovial proliferation.  
 
The key step in all both aerobic and anaerobic respiration is the breakdown of glucose 
to 2x pyruvate and producing 2x ATP in the process. A number of other energy sources 
may be converted to intermediaries directly including fructose and sucrose.  
 
Glucose + 2 NAD+ + 2 Pi + 2 ADP → 2 pyruvate + 2 NADH + 2 ATP + 2 H+ + 2 H2O 
 
Under aerobic conditions mitochondrial pyruvate dehydrogenase complex oxidizes 
pyruvate to acetyl-CoA and CO2 + NADH. This link reaction provides the initiation for the 
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citric acid cycle and subsequent oxidative phosphorylation producing the majority of 
cellular energy (a maximum of 36-38 ATP/glucose molecule). In contrast, under 
anaerobic conditions, hypoxia inducible factor HIF-1α induces pyruvate dehydrogenase 
kinase, inhibiting the conversion of pyruvate to acetyl-CoA in favour of fermentation to 
lactate32. Hypoxia inducible factors (HIFs) are transcription factors activated in response 
to decreases of oxygen in the cellular environment. A constitutive HIF-1b subunit 
associates with HIF-1a, 2a or 3a. These alpha-HIFs are extremely short-lived under 
oxygenated conditions degraded by pVHL. However, hypoxia disrupts pVHL/HIF-a 
interaction, leading to persistence, interaction with HIF-1b and induction of 
transcription33. Recent studies have shown macrophage expression of HIF-1a in the 
synovium of rheumatoid arthritis joints, but not in normal or osteoarthritic joints which 
are not hypoxic34. In a mouse model of arthritis, targeted deletion of the HIF-1a gene 
resulted in a marked reduction of inflammation and macrophage infiltration32 – strongly 
suggestive of a role for macrophage responses to hypoxia in rheumatoid arthritis. A 
possible mechanism of action is shown through the essential role of HIF-1a in the 
regulation of macrophage glycolysis. Loss of HIF-1a is associated with impaired 
aggregation, motility, invasiveness and killing of bacteria32. Importantly, it has been 
demonstrated in mouse macrophage cell lines that bacterial LPS is able to stimulate 
transcription of HIF-1α in the absence of hypoxia35 – providing an alternate route to 
these responses.  
 
That such phenotypic changes are observed in response to the hypoxic conditions of the 
wound site is strongly suggestive of a role for metabolism in regulation of macrophage 
activity. While normal wound resolution is a tightly regulated process, the presence of 
long-term inflammatory diseases such as rheumatoid arthritis is indicative of the 
potential for this regulation to go awry. Sites of chronic inflammation are associated 
with continued hypoxic, poorly perfused tissues high in lactate, and the associated 
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activation of tissue-resident macrophages. A preponderance of inflammatory M1 
phenotype is also seen, indicative of ongoing inflammatory process. It is unclear 
whether macrophages are driving or responding to the local tissue conditions, but it is 
likely that both are occurring. As previously described resolution is dependent on 
reperfusion and loss of hypoxia, and failure of achieve this may be the driving factor in 
continued inflammation.  However, while the inflamed site exists in a self-maintaining 
environment, the responsiveness of macrophages to changes in this environment may 
provide a route to manipulating and ultimately resolving the chronic inflammation. 
Macrophage responses to hypoxia, and subsequent changes in metabolic profile of the 
cells may offer targets for intervention – and manipulation of macrophage metabolic 
pathways, driving respiration via a deactivating or M2-favouring route, may offer a local 
and well tolerated mechanism of treatment. 
1.5 Metabolomics 
Metabolomics is a novel systems approach that allows us to address these questions. As 
transcriptomics involves the study of gene expression, and proteomics the expression of 
proteins, metabolomics investigates the downstream consequences and phenotypic 
effects of the activity of these genes and proteins. A hypothesis-forming approach, it 
starts with analysis of the whole population of small molecular metabolites across the 
whole population of individuals or samples under study. Data produced may be 
analysed as-is or frequency binned to reduce the quantity of the data for analysis. 
Quantification is then performed on peaks, without prior identification, to isolate the 
peaks or peak collections associated with a particular group of patients, conditions, or 
cellular profiles. Through this map of metabolites, metabolomics provides a window on 
the underlying functionality of the system. In studies of patient biofluids access to the 
metabolome allows integration of patient health and genetic profile with environmental 
effects to provide a complete picture of the disease state36 and so aid prediction of 
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outcome. Repeated sampling allows for understanding of the dynamic processes at work 
that may differentiate, or predict patient outcomes - perhaps identifying markers in 
patients for responses to treatment. Such discoveries may prevent unnecessary 
ineffective intervention, and more rapid, targeted treatments.  
 
These benefits extend to the lab, where the ability to take repeated whole-system 
measurements of metabolic processes is a valuable method for longitudinal phenotypic 
analysis. Importantly, the ability to use the same technique to analyse biofluids and 
cultured cell samples allows for more direct comparisons – and identification of where 
comparisons fail – informing experimental design. 
1.6 NMR spectroscopy 
Nuclear magnetic resonance is a phenomenon that may be observed when atoms are 
subjected to both a static background magnetic field and a secondary oscillating field. 
Under these conditions interactions between those atoms which possess a ‘spin’, which 
may be considered a small magnetic field of their own, interact with the larger fields in a 
predictable and measurable way.  
 
Spin is a fundamental property of all atomic particles, including electrons, protons and 
neutrons. Spin quantities are in ½-spin multiples and may be positive or negative. 
Individual unpaired electrons have a spin of ½, whereas electron pairs (one positive, 
one negative spin) effectively cancel out the overall observable spin. As such, it is 
unpaired atomic particles that are detectable and of interest in NMR spectroscopy. 
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Nuclei  Neutrons Protons Unpaired N+P Net Spin γ (MHz/T) 
1H  1 0+1 1/2 42.58 
2H 1 1 1+1 1 6.54 
31P 16 15 0+1 1/2 17.25 
23Na 12 11 2+1 3/2 11.27 
14N 7 7 1+1 1 3.08 
13C 7 6 1+0 1/2 10.71 
19F  10 9 0+1 1/2 40.08 
Table 1. Nuclei commonly used in NMR study 
 
For example, deuterium 2H, with a single proton, neutron & electron, has a ½ electronic 
spin, and a nuclear spin of 1. In contrast, helium 2He, with two neutrons, two protons 
and two electrons, has a zero electronic and nuclear spin, and as such is undetectable. A 
list of nuclei commonly used in NMR is shown in Table 1. 
 
The spin of the charged proton creates a magnetic moment vector leading to the proton 
acting as a small magnet itself. When placed in an external magnetic field the proton 
aligns with this in either a low energy N-S-N-S or high energy N-N-S-S configuration, and 
transitions between these states can be induced by photons of equivalent energy. The 
proportion of spins at high and low energy levels is relative to the temperature of the 
sample, and as temperature is decreased the majority of spins moves to lower energy 
state. The signal observed in NMR spectroscopy is relative to the difference between 
energy absorbed by moving to higher energy states and that released by moving to 
lower energy states, and therefore to the relative population quantities of each. These 
interactions, once measured form the basis of the NMR spectroscopy signal 
 
Data produced is in the form of time domain data, and is subsequently processed via 
Fourier transform (FT) to produce frequency domain data – the frequency peak graph. 
Molecules have unique, recogniseable patterns of peak frequencies and intensities from 
which it is possible to derive both the metabolite detected, and in comparison to a 
known standard, the concentration in the solution. Mapping identified metabolites onto 
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established metabolic pathways allows for development of regulatory maps, indicating 
up and down regulation of metabolic enzymes, providing valuable information for 
further targeted studies.  
1.7 Research goals and study methods 
The purpose of this study is to test the hypothesis that differentiated macrophages will 
display profoundly different metabolic profiles that are indicative of function.  
 
Primary blood monocytes will be grown under normoxia (20% oxygen) and hypoxia 
(1% oxygen) to simulate the conditions likely to be found in inflammatory sites. Effects 
of this manipulation on the metabolic profiles of the cultured cells may indicate an 
adaptation to the inflammatory environment or phenotypic change directing alternate 
function. Differentiation of these monocyte precursors to macrophage and dendritic 
cells, under different conditions, will be used to demonstrate the effects of environment 
on underlying metabolic profile. Subsequently cultured cells will be stimulated with LPS 
to assess the effect of both culture conditions and underlying physiology on response. 
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2 Materials & Methods 
2.1 Culture media & solutions 
Culture media RPMI    500ml 
10% fetal calf serum 50ml 
1% L-glutamine 5ml 
1% Penicillin/streptomycin 5ml 
Table 2. Culture media 
 
M1 RPMI + 1% GPS + 10 % Hi FCS GM-CSF 4ul 
M2 RPMI + 1% GPS + 10 % Hi FCS M-CSF 4ul 
DC RPMI + 1% GPS + 10% Human Serum GM-CSF 10ul 
IL-4 10ul 
Table 3. Primary monocyte differentiation media 
 
Coating buffer (10x stock) Sodium carbonate 1.36g 
Potassium bicarbonate 7.35g 
- Make up to 100ml H20  
- Adjust to pH9.2 1M HCl/1M NaOH  
Blocking buffer PBS 500mls 
Bovine serum albumin 5g 
Tween 250µl 
Wash buffer PBS 5L 
Tween 2.5ml 
Table 4. ELISA buffer solutions 
 
40% D20 60mls 
100mM Pi 156ml 2.34g 
2mM TMSP 51.6mg 
0.08% Azide 120mg 
Made up to 150mls with H2O 
Table 5. NMR buffer solution 1x 
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2.2 PBMC separation from whole blood 
Blood was obtained from donations from apheresis cones obtained from the NHSBT, 
Birmingham. Blood was diluted in an equal volume of PBS and layered on top of FicollP-
Paque. Samples were centrifuged at 1800rpm for 30 minutes at room temperature. The 
separated PBMC layer was removed, washed twice in 50ml PBS at 1600 and 1200rpm 
and re-suspended in 10ml RPMI, 1% FCS. The total PBMC count was made and B cell 
numbers determined by assuming B cells account for 5% of total PBMC. 
2.3 Isolation of monocytes from PBMCs 
Isolation of monocytes from PBMCs was performed by magnetic activated cell sorting 
(MACS) as per instructions from Miltenyi Biotec. Briefly, PBMCS were incubates with 
80ul MACS buffer per 107 cells, and MACS CD14 beads added at 20ul per 107 cells for 15 
minutes at 4’C. Cells were washed in 1ml MACS buffer per 107 cells then resuspended in 
500ul MACS buffer per 108 cells (5ml/107). MACS column was placed in a magnetic field, 
rinsed through with 3mls MACS buffer solution, and cell suspension was added. Column 
was washed with 3x 3mls MACS buffer, and run-off collected as waste. Column was 
transferred to collection tube, with 5ml buffer and syringed to collect cells. Purity of 
resulting samples was confirmed by flow cytometry. 
2.4 Cultured cells from liquid nitrogen storage 
Cells were transferred from cryovials into 6ml pre-warmed media in 15ml tube then 
centrifuged down for 6 minutes at 1200 rpm to pellet. Supernatant media was poured 
off and cells resuspended in 2mls RPMI+10% FCS then transferred to 25cm2 flask. Cells 
were incubated overnight, then transferred to 75cm2 flask to culture. 
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2.5 Primary monocyte differentiation 
Isolated primary monocytes were seeded at 3x106 cells/well in a 6 well plate, in 4ml 
media of appropriate type for differentiation (see Table 3). Cultures were incubated for 
3 days until initial signs of differentiation and adherence occurred. Supernatant media 
was removed carefully, avoiding disrupting loose cells, and replaced with 4mls fresh 
media of the appropriate types. After a further 3 days cells were fully differentiated for 
stimulation, or assay use. 
2.6 Primary monocyte normoxia, hypoxia, reperfusion assay 
To assay the metabolic effects of hypoxia and reperfusion on M1, M2 and DCs, these 
were differentiated as previously described in hypoxic conditions. Media for hypoxic 
cells was pre-exposed to hypoxic conditions for 1 hour prior to first use, and kept in 
hypoxic conditions for the duration of the experiment.  
 
At day 3 and day 6 media was removed from cell cultures and frozen down in cryovials 
for subsequent analysis, and appropriate media for the cultures was replaced. Feeding 
of hypoxic cells was carried out in the same hypoxic station. Normoxia and reperfusion 
cells were fed with normoxia-exposed media, with reperfusion cells removed from the 
hypoxic station for feeding then replaced to re-acclimatise. On day 6 10ng/ml 
lipopolysaccharide (LPS) was added to half of the cell cultures, and then left overnight. 
Media was again removed from all cultures to freeze down and remaining cells were 
retrieved as described below. 
2.7 Cell metabolite extraction for metabolomic analysis 
All remaining media was removed from the cells via pipette, and cells were washed with 
1ml PBS. Adhered cells were air-dried for 15 minutes and then 400ul methanol was 
added to each well and cells dislodged to solution via cell scraper. Solutions were 
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pipetted up and down to dislodge cells further and isolate to single cell suspension then 
transferred to glass vials and placed immediately on dry ice then transferred to -80’C. 
 
The following day glass vials were retrieved from the -80’C. Once defrosted, 325ul pre-
chilled distilled H20 was added to each tube via pipette. Next, 400ul pre-chilled 
chloroform was added to each tube with a blunt-ended Hamilton syringe and the 
samples were vortexed for 30 seconds to mix thoroughly. Samples were then 
transferred to the cold room for 10 minutes to allow phases to separate and then 
centrifuged at 4’C in swingout rotor at 1200rpm for a further 10 minutes. Once 
completed, vials were removed from the centrifuge to the bench and left to stand for 5 
minutes. The upper (polar) layer 400ul was transferred to eppendorf tubes and stored 
at -80’C overnight. The following day samples were dried in vacuum dryer for 3-4 hours, 
and resulting tubes were re-frozed at -80’C until prepared for NMR. 
2.8 NMR sample preparation 
Samples of 600ul each were prepared from dried cell extract or cell media and aliquoted 
to eppendorf tubes. 200ul of NMR buffer was added to each sample, to give a final 
volume of 800ul. Samples were adjusted to pH 7.1-7.2 by addition of 3M HCl (~1ul) then 
600ul was loaded to glass NMR tubes and kept at 4’C until required. 
2.9 Metabolomic analysis 
NMR data collected were phase corrected manually with Bruker XWin-NMR. Bruker 
datasets were subsequently imported into MatLab and processed using ProMetab v3.3. 
This performs a number of optimisations, including adjustment to equivalent total 
surface area, to account for variations in concentration, and log transformation to enable 
analysis of the full range of detected quantities. Finally, datasets were binned to 
0.01ppm bins to reduce the quantity of data for analysis. 
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2.9.1 Genetic algorithm (Galgo) 
Initial process was performed using genetic algorithm Galgo (ref) on exported datasets. 
A number of scripts were written to automate this process, as well as enabling easier 
analysis of combinations of classifiers. Briefly, Galgo treats each binned peak as a ‘gene’, 
with which it iteratively builds models through a stochastic process. Each model is then 
used to predict a sample’s membership of pre-defined classes. Over a number of 
generations the relative value of a gene, or group of genes, to describe each sample 
becomes apparent – and these are identified, rated and output at the end of processing. 
 
Such fitness data can then be used to draw principal-component space maps, identify 
key metabolites, or test further samples to establish the predictive nature of the model. 
2.9.2 Metabolite identification 
Metabolites were identified by manual matching of representative, original spectra, 
against a database of known spectral signatures. Binned spectra were then used to 
graph relative quantities of metabolites in different samples. Where multiple resonant 
peaks or peaks spanning multiple bins, exist for metabolites, a summed total of peaks 
was used to correct for interference from adjacent peaks or signal noise. 
 
Identified quantities were then mapped onto pre-mapped metabolic pathways to 
attempt to elucidate the implications for cellular respiration and function. 
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3 Results 
3.1 Cell media as an indicator of intracellular metabolism 
Metabolite extraction from experiment-terminal cells provides an overview of cellular 
metabolism at that time only. Using the same technique for timecourse experiments 
would require large duplication and therefore excessive cell numbers. In order to 
establish the viability of growth media analysis for metabolomics study we here have 
performed metabolic analysis of both terminal cell extracts and experimental cell media. 
 
Samples from cell culture at final timepoint of 8 days were analysed by NMR and 
resulting spectra binned as previously described. Metabolites were identified and 
relative levels of each metabolite compared as detected by the two methods.  
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Figure 4. Key metabolites identified by Galgo analysis (see later) here shown at relative levels 
detected by ppm in media vs. those detected from cell extracts at day 8. Generally a similar 
profile is observed, with minor variations in quantity except for isoleucine and threonine levels, 
which are much reduced in media vs. extracts of intracellular metabolites. 
 
Results (Figure 4) show highly similar profiles obtained from analysis of cellular growth 
media and isolation of metabolites from whole cell extracts, with the notable exception 
of isoleucine and threonine levels in media significantly lower. 
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Therefore, it is suggested that cell culture media provide an accurate and representative 
means to assay cellular metabolic processes in culture, and provide an accurate 
representation of cellular function. Comparison of relative levels in media must take 
these differences into account.  
3.2 Differentiating monocytes display different metabolic phenotypes 
To determine the baseline metabolic differences between M1, M2 and DC cells 
undergoing differentiation in normal culture conditions cell media were taken from cells 
at day 3 post-culture under 20% oxygen in cell differentiation media. Media NMR 
spectra were analysed using Galgo genetic algorithm to identify key metabolite peaks 
distinguishing the cell types. 
 
Resulting analysis shows that analysis of cell culture media allows full distinction 
between the three monocyte derived cell cultures, M1, M2 and DCs respectively. Highest 
identifiable ranking metabolites reported by Galgo are Alanine (ppm 1.5925) and Serine 
(ppm 3.9625) (Figure 5). As shown in Figure 6 top ranked metabolites do not necessary 
vary the largest amount, but do so consistently. A full listing of key metabolites 
identified in this manner is given in Table 6 and Figure 6 with levels of lactate, 
pyroglutamate, alanine and isoleucine being particularly striking.  
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Figure 5. M1, M2, DC (Hypoxia) cell differentiation by two metabolites at timepoint 1 & 2 
respectively. Galgo analysis demonstrates full separation of the 3 cell types is possible by the 
respective levels of just 2 metabolites Arginine (1.5925) and Serine (3.9625). 
 
Ppm Rank Metabolite 
1.5925 1 Arginine 
3.9625 2 Serine 
2.4825 3.5 Pyroglutamate 
4.1625   
1.6125 5.5 Arginine 
2.0625 7 Homoserine 
2.0775   
0.9925 8 Isoleucine 
1.3025 10 Lactate 
3.6875 11 Glucose 
Table 6. List of key metabolites identified by Galgo to contribute significantly to differentiating 
M1, M2, DC profiles during first 7 days. A number of lower-ranked peaks were not identified. 
 
 
 
23 
Key Galgo-identified metabolites in  M1, M2, DCs
under normoxic conditions
p
p
m
A
rg
in
in
e
S
er
in
e
-0.15
-0.10
-0.05
0.00
0.05
0.10
M1
M2
DC
**** **
 
Key differentiating metabolites in  M1, M2, DCs
under normoxic conditions
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Figure 6. Key metabolites, identified to differentiate M1, M2 and DCs shown for comparison 
relative to baseline media levels at 5 days. Arginine and serine levels are sufficient to 
differentiate macrophages and DCs (p<0.0001), and M1s and DCs (p<0.001). 
 
3.3 Macrophage metabolism altered by culture environments 
To analyse the effects on metabolism of culture under various conditions the complete 
set of identifiable peaks across all samples were studies. Where matched bins related to 
the same metabolite, these were grouped and a maximum value taken for the metabolite 
as a whole – reducing the data set and improving the consistency and accuracy of results 
from noise. Samples of differentiation media, treated identically to the samples, were 
used as a baseline for graphing purposes. 
 
Additionally, longitudinal analysis was performed with Galgo to rank the identified 
metabolites for their relative contribution to changes between the studied timepoints. 
Note as cell media were replaced at each timepoint, relative levels at each timepoint are 
indicative of production from metabolism over the preceding number of days. 
Additionally the possibility of ongoing replication cannot be excluded. Therefore, direct 
comparisons between timepoints are difficult. However, within-timepoint comparisons 
of differentiated macrophages subsets in various environments are outlined below. In 
order to account for media replacement, charts of relative change are based on baseline 
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readings of media, from the same stock and subject to identical treatment as the 
cultures. 
3.3.1.1 Metabolic effects of differentiation under different conditions 
M1 metabolic changes under
different culture conditions
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M2 metabolic changes under
different culture conditions
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Figure 7. Relative ppm of key metabolites from baseline media to day 5 culture. Note M1 and M2s 
keep their unique profiles, with minor variations in response to culture conditions. 
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Figure 8. Energy source changes during culture. Note the increase in medium glucose in M1 
cultures 
 
To assess initial effects of exposure to hypoxic conditions, monocytes were 
differentiated under various conditions and media were collected at day 5. Metabolic 
differences arising from both differentiation of the M1 and M2 subsets, and the various 
culture conditions, are apparent. Base culture media, taken from same time-point, and 
treated identically to the cultures is used for baseline on these graphs. Therefore, a fall 
in metabolite levels is indicative of consumption of given metabolite by cells in culture, a 
rise is indicative of production or release as degradation products.  
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By day 5 culture under hypoxic conditions, metabolic conditions were broadly 
unchanged from those outlined previously under normoxia. Most significantly observed 
is a slight decrease in betaine and pyroglutamate detected in media of hypoxia-cultured 
M1 macrophages, but not in M2s. Reperfusion culture results in more striking 
differences, with an increase in media betaine in M1 cultures and a reduction in M2s. 
Also notable in both cultures is a significant increase in pyruvate. Perhaps surprisingly, 
anaerobic culture results in only minor alterations in lactate levels, with both M1 and 
M2 macrophages maintaining their inverse profiles. 
3.3.1.2 Metabolic effects of culture under different conditions 
M1 metabolic changes under
different culture conditions
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M2 metabolic changes under
different culture conditions
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Figure 9. Relative ppm of key metabolites at day 7 of experiment relative to baseline media. 
 
To assess longer term effects of exposure to different oxygenation levels, macrophages 
were cultured out to 7 days with replacement of differentiation media at regular 
intervals. Key metabolites identified as differentiating M1 and M2 macrophages, and of 
culture under different oxygenation levels were considered.  
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By day 7 of culture a number of subtle changes have occurred. Metabolic profiles of 
reperfusion-cultured cells tend towards those seen in normoxia particularly with regard 
to relative levels of betaine and pyroglutamate in media. Both M1 & M2s also display 
broadly similar profiles for these key metabolites by this timepoint although 
distinguishing features remain, such as higher levels of alanine in media from M1s under 
normoxia. Interestingly, the inverse lactate profile seen between M1 and M2s is no 
longer present, with negative lactate (albeit small) observed in M2s under hypoxia. 
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3.4 Macrophage metabolism following LPS stimulation 
As demonstrated by the IL-10 data oxygenation conditions can have profound effects on 
the relative responses of M1 and M2 macrophages. To further investigate these effects 
with regard to the metabolism of these cells, the cell media and extracts of both 
stimulated and unstimulated cells from the final timepoint were analysed. 
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Figure 10. Key metabolites in cell media following LPS stimulation showing relative level of each 
metabolite from stimulated vs. unstimulated cultures (top) and bare metabolite levels (bottom). 
Note that although the profiles of M1 and M2s are broadly similar after LPS stimulation, no 
change is recorded in M1s under reperfusion.  
 
Across the board metabolic responses are relatively muted, however distinct profiles 
are observed for both M1 and M2s responding to LPS stimulus and under different 
conditions. Broadly, stimulation with LPS is associated with increases in lactate and 
pyroglutamate levels in the culture medium under normoxia and hypoxia. 
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M1 macrophages respond similarly under normoxia and hypoxia, with increases in 
lactate (as previously observed at early timepoints) and pyroglutamate, and reductions 
in glutamine and betaine, while under reperfusion culture, little to no metabolic 
alteration is observed between normal culture and LPS stimulation. In contrast M2s 
respond to LPS stimulation under reperfusion culture with reductions in betaine, 
pyroglutamate and lactate levels. Under hypoxic culture both lactate and pyroglutamate 
are similar to those in stimulated normoxia, although betaine levels are reduced.  
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Figure 11. Key metabolites in cell extracts following LPS stimulation showing relative level of 
from stimulated vs. unstimulated cultures. Relative profiles of both M1 and M2s are similar 
except for those highlighted in the bottom panel. 
 
Cell extract metabolite levels more variable, perhaps reflecting relative complexity of 
extraction and preparation process. Interestingly, aside from the key metabolites 
identified by Galgo in the media, there are considerable differences between M1 and M2 
metabolism following LPS stimulation, with M2s recording a significant drop in 
guanidoacetate, betaine and glycine (a pre-cursor of guanidoacetate). 
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3.5 IL-10 production confirms differentiation  
Production of IL-10 is observed in M1 and M2 macrophages following stimulation with 
LPS, but not dendritic cells.  ELISA assay of culture media following stimulation with LPS 
confirms the production of IL-10 by both M1 and M2 cultures, but not DC cultures. 
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Figure 12. IL-10 production in pg/ml by LPS stimulated differentiated M1, M2 and DCs under 
normoxia, hypoxia and reperfusion. M2 production of IL-10 is significantly reduced under 
hypoxic conditions. 
3.6 IL-10 production by M2 macrophages is reduced under hypoxia 
IL-10 production by differentiated M1, M2 and DCs grown under normoxia, hypoxia and 
reperfusion was assessed via ELISA. Unstimulated M1, M2 and DCs produce negligible 
IL-10 under normoxic, hypoxic or reperfusion conditions. A slight increase is observed 
under hypoxia. Under hypoxia IL-10 production by M1 macrophages remains at 
comparable levels to that observed under normoxia, while M2 macrophages display 
significantly reduced levels. Production of IL-10 under reperfusion is between that 
observed in normoxia & hypoxic conditions. 
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4 Discussion 
Macrophages are a broad family of monocyte-derived cells with a wide range of 
immunological and non-immunological functions, from clearance of erythrocytes in the 
liver to release of inflammatory mediators at the site of infection. Specific tissue-
resident macrophages are phenotypically adapted to their role, and studies on monocyte 
culture lineages have shown underlying metabolic differences in these subsets. It is not 
yet known however the extent to which recruited macrophages, differentiating in the 
tissues in response to stimulation, differ in their underlying metabolic signatures.  As 
outlined earlier, metabolic differences may have profound effects on the function and 
effectiveness of these cells, with implications for chronic inflammatory disease.  
4.1 Media offers representative indication of cell metabolism 
A key requirement for this series of time-course experiments was the ability to perform 
longitudinal analysis of cellular metabolic function in response to different stimuli. As a 
result, the availability of a non-destructive method for this analysis was essential and 
cell culture medium offered a viable solution. However, it was unclear whether the 
quantity of media the cells were cultured under would dilute relatively minor changes in 
metabolite quantities, or whether components of the original media would swamp 
detection. Our first key finding therefore, was that NMR analysis of cell culture media 
provided comparable and similarly variable levels of detected metabolites, with the 
notable exceptions of isoleucine and threonine. It is worth noting that the relative levels 
of metabolites in the media are not solely indicative of culture, but also of metabolites 
present in the original culture medium. As such the observed similarity may be 
accounted for by rapid uptake of growth media components by the macrophages in 
culture. Regardless, the results demonstrate that the conditions in the external media 
are largely representative of those intracellularly. Subsequent experiments attempted to 
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correct for the media contribution to metabolite levels by comparison with a baseline 
analysis of neat media. Unfortunately no such baseline exists for cell extracts, therefore 
in further study it would be beneficial to perform metabolomics analysis of pre-culture 
macrophages isolated in the same manner, to ascertain baseline levels of metabolites in 
primary cells.  
4.2 Differentiating monocytes display altered metabolic profiles 
In order to determine whether differentiation of monocytes resulted in cells with 
distinctive metabolic profiles, which in turn may reflect their function, the metabolic 
profiles of differentiating M1, M2 and DCs were determined at 5 days culture under 
different conditions. As described the highest ranking metabolite differences, identified 
by genetic algorithm, include alanine and serine, but with large differences also noted 
with lactate, pyroglutamate, alanine and isoleucine. It is the profiles of the M1 and M2 
macrophages that will be concentrated on here. 
 
Most striking through the early differentiation and culture process is the mirror-image 
levels of lactate observed in the two macrophage cultures. Observed levels were 
calculated relative to baseline media samples and show a large reduction in detectable 
lactate levels in M1 culture, in stark contrast to high levels observed under M2 culture. 
Lactate is a key component of glycolysis / gluconeogenesis and pyruvate metabolism. 
Importantly levels of pyruvate detectable in media are unchanged (data not shown) at 
this time-point, excluding pyruvate metabolism or glycolysis, while levels of glucose are 
shown to increase. Gluconeogenesis is the metabolic process of formation of glucose 
from non-carbohydrate sources, and is typically considered restricted to the liver, 
although one gene variant, PFKFB3 has been shown to be active in a number of human 
tumour cell lines37. Interestingly, the gluconeogenic enzyme fructose-1,6-
bisphosphatase has been shown to be activated in monocyte-derived Hl60 line under 
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vitamin-D3 driven differentiation, and is also found in alveolar macrophages38. It is 
possible that glucose production in M1s is a side effect, as the target of fructose-1,6-
bisphosphatase, the glycolysis intermediate fructose-1,6-bisphosphate, also has anti-
inflammatory and anti-histiminic functions39. M1 macrophages undergoing 
differentiation may therefore be acting to remove early anti-inflammatory stimulus 
while providing an energy source to enable rapid expansion of responses in tissues with 
limited blood supply. This relative excess of glucose in M1 cultures appeared to be 
short-lived and differentiation-associated. By day 7 levels of glucose in M1 culture had 
fallen, as had levels of fructose, suggesting either an end of production or demand 
exceeding synthesis capacity.  
 
The distinct profile of M1 and M2s was largely lost by day 7, with the mirrored levels of 
lactate returning to comparable levels, with M2s under hypoxia now showing the lowest 
levels. Metabolic differences therefore appear to be restricted to differentiation and 
perhaps activation. However, a small but significant drop in arginine levels at day 7 in 
M1s particularly may coincide with HIF-1 mediated upregulation of genes coding 
arginases and iNOS27, which coincide with increased TNFa and IL-6. While nitric oxide 
has vasodilatory functions, synthesis is paradoxically oxygen dependent. Released as a 
free radical however, it has potent antimicrobial activity in. In increased hypoxia, a shift 
towards urea and ornithine production may be expected unfortunately neither 
metabolite was identifiable from spectra. Interestingly, increased levels of urea have 
been shown to inhibit the activity of pyruvate kinase, while betaine mitigates this 
behaviour40. Betaine levels were reduced following stimulation in hypoxia.  
4.3 Stimulated macrophages have shared metabolic profiles 
Stimulation of differentiated macrophages results in a metabolic profile as outlined in 
Figure 10. It is interesting to note that differences observed between M1 and M2s during 
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differentiation are no longer apparent, with the exception of slightly higher lactate level 
in M1s. Relative profiles between stimulated and unstimulated macrophages show a 
common increase in lactate and pyroglutamate levels in culture and a fall of betaine 
under hypoxia, and glutamine falling in M1s under normoxia and rising under hypoxia. 
4.3.1.1 M1 macrophages, reperfusion and intrinsic activity 
The most striking result from the stimulation experiments is the complete absence of 
metabolic change detectable in stimulated M1 macrophages cultured under reperfusion 
conditions. It is important to note that results here are relative to unstimulated 
macrophages cultured under the same experimental conditions. In figure Figure 10 the 
bare metabolite levels are shown demonstrating that the reperfusion response in M1s is 
equivalent to those under other conditions. Therefore, rather than indicating a lack of 
response in reperfusion conditions, the metabolic profile observed may be indicative of 
instrinsic activation of M1 macrophages under reperfusion conditions. 
 
Because of an association inflammation and hypoxia in the inflamed tissues, the use of 
hypoxia as a trigger for activation is not suprising. However, while a viable strategy 
under normal conditions, infiltration of immune cells, including macrophages, to 
unusual persistently hypoxic sites – such as the rheumatoid synovium – may provide a 
link from structural hypoxia to abherrant activation. Once initiated, the release of 
cytokines may drive further infiltration of immune cells to a similar fate, driving a 
cascade of inflammatory response. Reperfusion injury in vivo may be indicative of local 
tissue damage or a natural effect of monocyte migration from the circulation to injured 
or damage tissues. Local structural damage in joints provides another route for transient 
reperfusion via damage to locally inflamed blood vessels. 
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4.3.1.2 M2 macrophages response to stimulation affected by culture conditions 
Stimulation of M2s resulted in the expected increase in lactate and pyroglutamate 
previously described in both normoxia and hypoxia cultured macrophages. However, 
under reperfusion a drop in the same metabolites is recorded following stimulation. In 
contrast betaine levels fall under hypoxia and reperfusion, but increase under normoxia. 
Levels of fructose are increased relative to un-stimulated macrophages in both hypoxia 
and reperfusion, while levels of glucose fall - with culture under normoxia showing a 
mirrored profile suggestive of a switched energy profile in response to low oxygen. 
However, without further metabolites it is difficult to establish a model of these effects. 
4.4 IL-10 responses modulated by hypoxia 
A role for IL-10 in modulating inflammatory immune responses can be seen in a number 
of conditions. In reperfusion injury expression of IL-10 by infiltrating lymphocytes 
begins at 5 hours post-injury, peaking at 96 hours41. In contrast inflammatory responses 
such as TNFa and IL-6 are initiated almost immediately post-injury. The picture 
therefore is of a rapid expanding inflammatory response, followed by the gradually 
suppressive action of IL-10 release either by late arrivals to the inflammatory milieu or 
changing expression patterns of those already present. It has previously been shown 
that IL-10 is upregulated28 in macrophages in response to hypoxic conditions. However, 
here we have shown that while IL-10 is marginally upregulated in M1 macrophages 
under hypoxic conditions, production by M2s is strongly inhibited. The resulting balance 
of IL-10 in any hypoxic inflammatory site therefore is dependent on the relative 
numbers of M1 and M2 macrophages infiltrating. The discovery that M2s are capable of 
in situ replication in the tissues14 would suggest an excess would normally persist, 
therefore, the resolution of any inflammation may be heavily dependent on return to 
normoxic perfused states.  A potential functional benefit of this behaviour in vivo is clear, 
with much reduced inhibition of inflammatory processes in the early stages of infection, 
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where tissue damage and hypoxia are most severe. As tissue repair processes begin and 
perfusion returns, suppression of IL-10 release local tissue M2 macrophages is lifted, 
and the wound site can rapidly resolve.  Likewise, the potential for this mechanism to go 
awry under chronically hypoxic tissues, such as the rheumatoid synovium, is clear.  
4.5 Conclusions 
Bringing together these findings in an in vivo context a picture emerges of M1 
macrophages responding pre-adapted for the hypoxic conditions of the inflamed site. 
Differentiation in the tissues triggers up-regulation of fructose-1,6-bisphosphatase 
activity, with the dual effect of increasing local glucose – providing abundant energy for 
local proliferation in poorly perfused tissues – and simultaneous degradation of anti-
inflammatory fructose-1,6-bisphosphate. Only by later time-points are typical 
adaptations to hypoxia initiated, including potentially HIF-1α activation, also seen 
following LPS stimulation.  In contrast, differentiation to M2 is associated with increased 
lactate production largely independent of oxygen levels in culture. Production of IL-10 
following stimulation with LPS is however significantly reduced. 
 
In combination, the effect is of a reduced, or suppressed, anti-inflammatory response 
during initial infiltration of M1 macrophages, or under hypoxic conditions for M2 
macrophages. Together, these may act to prolong inflammation until either migration or 
M1 differentiation is interrupted, or reperfusion of the hypoxic tissues occurs. In normal, 
healthy, wounded tissues, this sequence of events may aid to prolong inflammation until 
resolution is appropriate. However, in chronically inflamed tissues, such as the 
rheumatoid synovium, persistent hypoxia combined with and aberrant infiltration by 
M1 macrophages may reinforce, prolong or even drive the pathological process. 
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Further study would benefit for a wider panel of identified metabolites, together with 
metabolic pathway mapping to build a fuller picture of these interactions. Due to time 
constraints all spectra used for this study were 1D, while NMR 2D or 1D JRES spectra 
separate resonance peaks onto a second axis, excluding or reducing interference from 
multiple metabolites and greatly simplifying identification, unfortunately at a 
considerable cost of time. However, single representative 2D spectra may provide 
sufficient information to build better models.  
 
Finally, key to understanding and interpreting these data is a complete understanding of 
the underlying processes that govern observations. Metabolic pathways are complex 
structures and data here described represent an assortment of midpoints and endpoints 
in these processes. With the addition of microarray gene transcription data it would be 
possible to characterise the on-going processes in the cell, through observations of 
changes in metabolic enzymes, and so both map responses and visualise routes from 
normal activity to chronic pathology. 
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